We use cookies to help provide you with the best possible online experience. Learn more

Press archive

    RayStation awarded treatment planning system tender at Canadian cancer center

    PDF

    Centre intégré de cancérologie de Laval, Montreal, Canada, has selected RayStation through the public tender process as its sole treatment planning system, replacing existing systems. The center welcomes residents of Laval and the surrounding areas since 2011.

    Centre intégré de cancérologie de Laval is equipped with four linacs, all Elekta Synergy with Agility MLC, as well as advanced imaging systems such as CT, PET-CT and MRI. The center plans for expansion with an additional linac to treat specialized cases.

    Key factors for selecting RayStation was its standardization and automation capabilities of the planning process for 3D-CRT and VMAT, additional optimization tools such as multi-criteria optimization (MCO), as well as the speed of dose computation and support for adaptive re-planning.

    Fadi Hobeila, Chief Medical Physicist at Centre intégré de cancérologie de Laval says: “We are a highly efficient and integrated cancer center with innovative workflows. We required a fully featured, flexible and efficient treatment planning system that would fit into our workflows and enable a next level of efficiency and quality for our patients. We look forward to implementing RayStation in our department clinically.”

    Johan Löf, CEO of RaySearch, says: “We are very glad to see that Centre intégré de cancérologie de Laval chose RayStation as its treatment planning system. The tender process in Canada has been intense and comprehensive. We have done well, and we are now working to effectively support these new centers in Quebec. We are excited to see what the future will bring in our collaboration with Centre intégré de cancérologie de Laval.” 

    This tender is the fifth public tender won by RaySearch in Canada over the past two years. At least one more RFP (request for proposal) tender in Canada is expected to be released during 2018.

    About Centre intégré de cancérologie de Laval

    Centre intégré de cancérologie de Laval, a part of Centre intégré de santé et de services sociaux de Laval Hôpital juif de réadaptation de Laval, was established in 2011, treating 2050 cancer cases annually. CISSS de Laval is dedicated to learning, innovating and excelling in order to provide the Laval population with integrated, accessible and quality health care and social services. Its human capital has more than 10,000 employees and physicians working in 32 facilities. CISSS de Laval is a research and teaching organization affiliated with the Université de Montréal and McGill University.

    About RayCare

    RayCare* represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    Peter Thysell, CFO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)70 661 05 59

    peter.thysell@raysearchlabs.com 

    PDF

    Provision Cares Proton Therapy Nashville uses RayCare to treat first patient

    PDF

    Provision Cares Proton Therapy Nashville, the newest member of the Provision CARES Cancer Network, successfully treated their first patient on October 8, utilizing the treatment planning system RayStation and the oncology information system (OIS) RayCare* to plan and manage its proton treatments. The brand-new center has been using RayCare together with RayStation since its opening in July this year. 

    The Nashville center features the new ProNova SC360 proton therapy system. It is the first clinic world-wide to connect RayCare directly to the treatment delivery system, using it to record and verify the treatment sessions; and the second clinic world-wide to use RayCare clinically. Provision CARES Proton Therapy Knoxville was the first center in the world to use RayStation for clinical proton treatment planning in 2014. 

    RayCare is an innovative OIS designed to support comprehensive cancer care. RayCare will provide one workflow to connect all the oncology disciplines, enabling users to coordinate tasks fluidly and ensure optimal use of resources. A new version of the OIS, RayCare 2B, was recently released. Key features include support for a full treatment delivery and management workflow and task-based offline image review. Other care administration features include support for financial information, such as insurance information and authorization management, and support for managing external contacts, referring clinicians and other external entities.

    Mary Lou DuBois, President, Provision Solutions, says: “We wanted to design this center around new technologies that would change the way proton treatments could be delivered. Our plans have come to fruition, and we look forward to a long partnership with RaySearch to continue to improve cancer care with advanced treatment planning and patient data management.”

    Johan Löf, CEO of RaySearch, says: “RaySearch and Provision with their ProNova system, are very much alike. We are both companies who are not satisfied with the status quo. It was a perfect partnership that began a couple of years ago as we both set out to provide new and better treatment approaches in proton therapy. We are excited that RayCare is now in daily clinical use, and we will continue to work with our collaborators around the world to make it the best OIS for all modalities into the future.”

    About Provision CARES Proton Therapy Network

    The CARES Cancer Network is focused on providing the most comprehensive and advanced cancer treatment options and solutions for cancer patients through innovative partnerships and strategic collaboration. This growing cancer network establishes new Standards of Excellence in cancer patient treatment, research and care.

    About RayCare

    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    Peter Thysell, CFO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)70 661 05 59

    peter.thysell@raysearchlabs.com 

    PDF

    RaySearch and Canon Medical enter into collaboration agreement

    PDF

    RaySearch Laboratories AB (publ) and Canon Medical Systems Corporation (Canon Medical) have entered into a collaboration agreement to facilitate a close integration between RaySearch’s advanced software products RayStation and RayCare*, and Canon Medical’s imaging systems and advanced visualization solutions.

    RayStation provides treatment planning functionalities and RayCare, the oncology information system and its imaging archiving and communication system, RayPACS, provides the image management and workflow tools.

    The collaboration, that will generate products that will initially be launched in the U.S. market, is expected to enable a more efficient workflow in the process of virtual simulation. By using radiotherapy imaging and planning tools, clinicians will be assisted in deciding how and where patients should be treated, determining the size and location of the tumor, planning the direction of radiotherapy beams and calculating appropriate iso-center locations.

    RayStation Simulation provides functionality for virtual simulation including patient modeling, isocenter placement, export to patient marking systems, and beam design. The functionality has been part of RaySearch’s comprehensive treatment planning system for more than two years. The oncology information system RayCare was released by RaySearch last year and it provides the image management and the necessary workflow for performing virtual simulation tasks.  

    RayStation Simulation and RayCare will provide a fully integrated workspace and a comprehensive toolbox together with Canon Medical’s imaging technologies. This tightly integrated solution will simplify the workflow and assist treatment planners to design the best radiotherapy treatment plan for the patient. 

    Toshio Takiguchi, president and CEO, Canon Medical, says: “This collaboration exemplifies Canon Medical’s ’Made for Life philosophy’, allowing us to provide clinicians and their patients with the combination of best-in-class medical imaging technologies along with best-in-class oncology informatics to deliver better quality care at a lower cost. Together through this partnership with RaySearch, we aim to bring further benefits of high-definition imaging to the oncology continuum of care.”

    Johan Löf, CEO of RaySearch, says: “We are very excited about our collaboration with Canon Medical, which will open up a new market for RaySearch where we can make a great difference. The agreement will help streamline workflows and aim to increase efficiency. We are looking forward to see where this relationship will take us in the future of advanced cancer care.” 

    About Canon Medical Systems Corporation

    Canon Medical Systems Corporation develops and manufactures diagnostic imaging systems including CT, MRI, ultrasound, X-ray systems and clinical laboratory systems and provides them to around 140 countries and regions around the world, offering technology that provides faster diagnosis and early treatment. Under the slogan "Made for Life" (Made for Partnerships, Made for Patients, Made for You), Canon Medical Systems is making positive contributions toward hospital management, and provides a range of patient-friendly healthcare systems and services, continuing its long tradition of contributing to healthcare.

    About RayCare

    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    Peter Thysell, CFO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)70 661 05 59

    peter.thysell@raysearchlabs.com 

    PDF

    Holland Proton Therapy Centre treats first patient using RayStation

    PDF

    Holland Proton Therapy Centre (HollandPTC) has started treating patients using RayStation as the treatment planning solution, in combination with the Varian ProBeam® System and the Varian ARIA® oncology information system.

    HollandPTC was the first proton therapy center established in the Netherlands. RayStation was selected over other treatment planning alternatives following an extensive tender process in 2016. RayStation received the highest assessment in several key areas, including adaptive therapy, connectivity, automation and scripting, user experience, and plan optimization. The agreement between RaySearch and HollandPTC includes both clinical and research licenses.

    Johan Löf, CEO of RaySearch, says: “We are glad to see that HollandPTC has completed its first patient treatment using RayStation. Proton therapy is an important area of focus for RaySearch, and we have designed RayStation to deliver on its therapeutic possibilities. I look forward to a long and successful relationship with HollandPTC, both for the clinical parts and also for research efforts.”

    About HollandPTC

    HollandPTC is an independent center for proton therapy and a partnership between Erasmus University Medical Center, Leiden University Medical Center and the Delft University of Technology. In addition to patient care, the center will provide education and conduct an extensive research and development program.

    About RayCare

    RayCare* represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    Peter Thysell, CFO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)70 661 05 59

    peter.thysell@raysearchlabs.com 

    PDF

    RaySearch releases a new version of the RayCare oncology information system

    PDF

    RaySearch Laboratories AB (publ) has released RayCare 2B*, the latest version of the groundbreaking oncology information system (OIS). RayCare is designed to support the workflow in a modern oncology center, connecting the different oncology disciplines, boosting efficiency and ensuring optimal use of resources.

    RayCare is developing rapidly with clinical input from some of the leading cancer centers worldwide, and this is the second of three releases during 2018.

    The first clinical version of RayCare was released in December 2017, and Iridium Cancer Network in Belgium started using it clinically after only two months. Provision CARES Proton Therapy Center in Nashville, USA, has been using RayCare together with RayStation to manage their patients since opening of the center in July this year.

    RayCare 2B introduces new features and usability improvements throughout the system, including a feature to support a full treatment delivery and management workflow and task-based offline image review. Other care administration features include support for financial information, such as insurance information and authorization management, and support for managing external contacts, referring clinicians and other external entities.

    Johan Löf, CEO of RaySearch, says: “The latest release of RayCare is an important step on the road we are paving for this OIS. The pace of the releases is set to support our clinical partners with a continuously strong development, redefining what an OIS is capable of. 

    About RayCare

    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    Peter Thysell, CFO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)70 661 05 59

    peter.thysell@raysearchlabs.com 

    PDF

    Swedish Cancer Institute selects RayStation for treatment planning

    PDF

    Swedish Cancer Institute in Seattle, US, the largest cancer institution in the Providence Health and Services network, has chosen RayStation as its primary comprehensive treatment planning system.

    RayStation has been in use at other Providence Health and Services network hospitals since 2013. Swedish Cancer Institute's order places the center as the 8th RayStation user within the Providence system, allowing these centers to share data as needed, enabling centralized operations and access.

    The purchase solidifies Providence Health and Services’ commitment to fostering an approach that takes advantage of the treatment planning efficiencies RayStation can provide on an enterprise level. 

    RayStation was selected by Swedish Cancer Institute following an evaluation of leading treatment planning systems on the market. Key factors in the decision included the system’s high efficiency and cutting-edge functionality such as multi-criteria optimization (MCO), adaptive planning, dose tracking and fallback planning.

    Dave Shepard, Director of Medical Physics at Swedish Cancer Institute, says: “As with many large radiation therapy treatment networks around the US, we have a need to consolidate our technical approach to treatment planning. We also needed to support several different linear accelerator vendors and patient data from disparate systems. Our goal is to become more efficient, at several different levels, while not compromising any aspect of patient care.”

    Johan Löf, CEO of RaySearch, says: “We are very pleased that Providence Health and Services network has chosen RayStation to continue their integration efforts. Our team will work hard to support the Swedish Cancer Institute, and we are confident that RayStation will deliver outstanding clinical efficiency, high speed and adaptive treatment workflows, and ensure the best possible treatment for its many patients. It is also rewarding to deliver our system to a center founded by a fellow Swedish doctor almost 90 years ago. We are excited to see the future of our collaboration with Swedish Cancer Institute and the Providence Health and Services network."

    About Swedish Cancer Institute

    Since 1910, Swedish Hospital has been the Seattle area's hallmark for excellence in hospitals and health care. Swedish is consistently named the Seattle area's best hospital, with the best doctors, nurses and overall care in a variety of specialty areas. The cancer center, Swedish Cancer Institute, has been a Seattle-area leader in innovative cancer diagnosis, treatment and recovery since 1932. The center is said to have cared for more patients than any other cancer center in the Northwest.

    About RayCare

    RayCare* represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    Peter Thysell, CFO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)70 661 05 59

    peter.thysell@raysearchlabs.com 

    PDF

    RayStation to replace existing treatment planning system at Leeds Cancer Centre

    PDF

    RaySearch strengthens its position in the UK market with a major order for the treatment planning system RayStation from Leeds Cancer Centre (LCC), UK. RayStation will replace the existing treatment planning system.

    LCC, part of Leeds Teaching Hospitals NHS Trust (LTHT) is one of the biggest centers in the UK, treating patients from the West & North Yorkshire region of 2.8 million residents. The ten-year-old facility is currently in the process of replacing all of its imaging and treatment equipment.  

    RayStation was chosen by the center after scoring highly in comparison with other competing systems. In particular, dose tracking and adaptive planning stood out as important functionalities. LCC will predominantly treat patients using VMAT, but 3D CRT and IMRT are also included in the order. The center will also use electron planning, AutoBreast, Multi-Criteria Optimization (MCO), RayStation Virtual Simulation and RayStation Doctor.

    John Lilley, Head of External Beam Radiotherapy Physics at Leeds Cancer Centre, says: “It's clear to me that using RayStation can transform the way that we work. Switching planning system is a massive undertaking but seeing how intuitive the software is and talking to other users I'm confident that the process will be smooth. The functionality that is available as standard in RayStation is impressive and we're sure that it will bring many benefits to planning our patients. We're confident that the improved functionality and efficiency savings that we'll be able to make will bring major benefits to the patients that we treat at the Leeds Cancer Centre. We’re really looking forward to collaborating with RaySearch.”

    Johan Löf, CEO of RaySearch, says: “We constantly remind ourselves that RayStation cannot be just slightly better than the competing systems. To justify the effort of changing from one system to another, or to move away from the perceived simplicity of a one vendor solution, RayStation has to provide significant advantages across a wide range of functionalities. With this in mind, we are glad to expand further in the UK with the order from LCC. RayStation has once again proven itself to be the premier treatment planning system. We are looking forward to the collaboration with another leading UK institution. 

    About Leeds Cancer Centre

    LCC is a part of Leeds Teaching Hospitals NHS Trust (LTHT), one of the largest teaching hospitals in Europe with over 18 000 staff. LCC, one of the largest cancer centers in the UK, opened in 2008. The center contains state-of-the-art imaging and treatment equipment and is dedicated to refresh and update the technology regularly.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RayCare

    RayCare* represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    Peter Thysell, CFO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)70 661 05 59

    peter.thysell@raysearchlabs.com 

    PDF

    Interim report January 1- June 30, 2018

    PDF

    RaySearch Laboratories AB (publ)

    “In the second quarter of 2018, order intake excluding service agreements rose 47 percent to SEK 160 M, which is the highest order intake ever for the second quarter. Net sales declined marginally to SEK 141 M (142) and the operating margin remained unchanged at 19 percent (19), mainly due to the change in accounting policies, but also to positive currency effects. Without application of the new accounting policies, net sales would have risen 15 percent to SEK 162 M and the operating margin would have been 28 percent. Our order backlog including service agreements was SEK 720 M (591) at the end of the period. We feel secure with our long-term strategy and our expansion will continue”, says Johan Löf, CEO of RaySearch.

    SECOND QUARTER (APRIL-JUNE 2018) 

    • Net sales SEK 141.0 M (141.6), of which revenues from RayStation®/RayCare® SEK 126.6 M (127.6) 
    • Profit after tax SEK 20.6 M (20.1), and earnings per share before/after dilution SEK 0.60 (0.59) 
    • Operating profit SEK 26.3 M (26.8) 
    • Cash flow SEK -50.3 M (-13.7) 
    • Order intake excl. service agreements SEK 160.3 M (108.8), of which RayStation/RayCare SEK 151.1 M (98.0)

    HALF-YEAR (JANUARY-JUNE 2018) 

    • Net sales SEK 257.3 M (268.4), of which RayStation/RayCare SEK 233.4 M (240.0) 
    • Profit after tax SEK 32.4 M (46.4), and earnings per share before/after dilution SEK 0.94 (1.35) 
    • Operating profit SEK 40.4 M (60.3) 
    • Cash flow SEK -37.9 M (-16.7) 
    • Order intake excl. service agreements SEK 266.7 M (213.7), of which RayStation/RayCare SEK 248.2 M (191.8) 
    • Order backlog incl. service agreements SEK 719.7 M (591.0) at the end of the period 
    • Order backlog for RayStation/RayCare excl. service agreements SEK 106,0 M (36.0) at the end of the period

     CHANGES TO ACCOUNTING POLICIES

    • IFRS 15 Revenue from Contracts with Customers came into effect on January 1, 2018, which reduced the company’s license revenue from RayStation and RayCare by 19 percent in the second quarter of 2018 and 16 percent in the first half of 2018 compared with the previously applied accounting policy (IAS 18), see Notes 1-2. The changed accounting policies also had a negative impact on net sales and earnings for the past 12-month period. 

    SIGNIFICANT EVENTS DURING THE SECOND QUARTER 

    • RayStation was selected by several leading cancer centers, including the Heidelberg Ion Beam Therapy Center (HIT) and Marburg Ion Beam Therapy Center (MIT) in Germany, Centre intégré universitaire de santé et de service sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (SHUS) in Quebec, Canada, and Advanced Oncotherapy (AVO) in the UK. 
    • Two RayCare orders were received – one from a center in Belgium, and one from a center in Colombia. 
    • Long-term collaborative agreements for RayCare were concluded with Heidelberg University Hospital in Germany and for brachytherapy with Eckert & Ziegler BEBIG. 
    • A research collaboration and long-term licensing agreement for carbon-ion therapy were concluded with NIRS/QST in Japan and will lead to the integration of NIRS’s Microdosimetric Kinetic Model (MKM) in RayStation. 
    • RayStation 8A* was released, with support for the TomoDirectTM treatment mode.

     SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

    • RayCare 2A* was released with a range of new features, including activity and rule-based scheduling for all clinical resources, clinical document management and additional treatment planning functionality. 
    • A long-term collaborative agreement for RayCare was concluded with the Princess Margaret Cancer Center in Toronto, Canada.

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on August 23, 2018 at 7:45 a.m. CET.  

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO          Tel: +46 8 510 530 00                   E-mail:
    johan.lof@raysearchlabs.com
    Peter Thysell, CFO                          Tel: +46 70 661 05 59                   E-mail:
    peter.thysell@raysearchlabs.com

     
    ABOUT RAYSEARCH

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to cancer centers all over the world and distributes the products through licensing agreements with leading medical technology companies. RaySearch’s software is currently used by over 2,600 centers in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at www.raysearchlabs.com. 

    PDF

    Interim report January 1- June 30, 2018

    PDF

    RaySearch Laboratories AB (publ)

    “In the second quarter of 2018, order intake excluding service agreements rose 47 percent to SEK 160 M, which is the highest order intake ever for the second quarter. Net sales declined marginally to SEK 141 M (142) and the operating margin remained unchanged at 19 percent (19), mainly due to the change in accounting policies, but also to positive currency effects. Without application of the new accounting policies, net sales would have risen 15 percent to SEK 162 M and the operating margin would have been 28 percent. Our order backlog including service agreements was SEK 720 M (591) at the end of the period. We feel secure with our long-term strategy and our expansion will continue”, says Johan Löf, CEO of RaySearch.

    SECOND QUARTER (APRIL-JUNE 2018) 

    • Net sales SEK 141.0 M (141.6), of which revenues from RayStation®/RayCare® SEK 126.6 M (127.6) 
    • Profit after tax SEK 20.6 M (20.1), and earnings per share before/after dilution SEK 0.60 (0.59) 
    • Operating profit SEK 26.3 M (26.8) 
    • Cash flow SEK -50.3 M (-13.7) 
    • Order intake excl. service agreements SEK 160.3 M (108.8), of which RayStation/RayCare SEK 151.1 M (98.0)

    HALF-YEAR (JANUARY-JUNE 2018) 

    • Net sales SEK 257.3 M (268.4), of which RayStation/RayCare SEK 233.4 M (240.0) 
    • Profit after tax SEK 32.4 M (46.4), and earnings per share before/after dilution SEK 0.94 (1.35) 
    • Operating profit SEK 40.4 M (60.3) 
    • Cash flow SEK -37.9 M (-16.7) 
    • Order intake excl. service agreements SEK 266.7 M (213.7), of which RayStation/RayCare SEK 248.2 M (191.8) 
    • Order backlog incl. service agreements SEK 719.7 M (591.0) at the end of the period 
    • Order backlog for RayStation/RayCare excl. service agreements SEK 106,0 M (36.0) at the end of the period

     CHANGES TO ACCOUNTING POLICIES

    • IFRS 15 Revenue from Contracts with Customers came into effect on January 1, 2018, which reduced the company’s license revenue from RayStation and RayCare by 19 percent in the second quarter of 2018 and 16 percent in the first half of 2018 compared with the previously applied accounting policy (IAS 18), see Notes 1-2. The changed accounting policies also had a negative impact on net sales and earnings for the past 12-month period. 

    SIGNIFICANT EVENTS DURING THE SECOND QUARTER 

    • RayStation was selected by several leading cancer centers, including the Heidelberg Ion Beam Therapy Center (HIT) and Marburg Ion Beam Therapy Center (MIT) in Germany, Centre intégré universitaire de santé et de service sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (SHUS) in Quebec, Canada, and Advanced Oncotherapy (AVO) in the UK. 
    • Two RayCare orders were received – one from a center in Belgium, and one from a center in Colombia. 
    • Long-term collaborative agreements for RayCare were concluded with Heidelberg University Hospital in Germany and for brachytherapy with Eckert & Ziegler BEBIG. 
    • A research collaboration and long-term licensing agreement for carbon-ion therapy were concluded with NIRS/QST in Japan and will lead to the integration of NIRS’s Microdosimetric Kinetic Model (MKM) in RayStation. 
    • RayStation 8A* was released, with support for the TomoDirectTM treatment mode.
     SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
    • RayCare 2A* was released with a range of new features, including activity and rule-based scheduling for all clinical resources, clinical document management and additional treatment planning functionality. 
    • A long-term collaborative agreement for RayCare was concluded with the Princess Margaret Cancer Center in Toronto, Canada.

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on August 23, 2018 at 7:45 a.m. CET.  

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO          Tel: +46 8 510 530 00                   E-mail:
    johan.lof@raysearchlabs.com
    Peter Thysell, CFO                          Tel: +46 70 661 05 59                   E-mail:
    peter.thysell@raysearchlabs.com

     
    ABOUT RAYSEARCH

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to cancer centers all over the world and distributes the products through licensing agreements with leading medical technology companies. RaySearch’s software is currently used by over 2,600 centers in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at www.raysearchlabs.com.

    PDF

    RaySearch and Princess Margaret Cancer Centre enter strategic partnership to shape the future of cancer treatment

    PDF

    RaySearch and Princess Margaret Cancer Centre – University Health Network in Toronto, Canada, have joined forces in a strategic partnership to further develop RayCare®*, a groundbreaking oncology information system designed for the clinical workflow needs of today and tomorrow.

    RayCare is designed to unify and consolidate the different oncology disciplines – medical oncology, radiation oncology and surgical oncology – paving the way toward precision medicine. The system will improve workflows across treatment modalities and meet the demands of new techniques and approaches in cancer treatment.

    The implementation of RayCare at Princess Margaret will follow a phased approach over several years. In each phase, capabilities will be added in RayCare and existing systems replaced. Ultimately, all activities in the oncology space will be coordinated through RayCare.

    Mary Gospodarowicz, medical director at Princess Margaret says: “We have a strong focus on comprehensive cancer care at the Princess Margaret and uniting the different clinical disciplines is a key priority. RayCare will enable us to achieve this. It will also provide us with an integrated cancer informatics platform that builds on the significant advances we have made in this area. This is a collaboration that will shape the future of oncology systems.”

    Johan Löf, CEO of RaySearch, says: “PMH is one of the most important cancer centers worldwide, and their experience and insight will be invaluable in the continuing development of RayCare. Our partnership, which spans more than a decade, is one of the pillars supporting RaySearch’s work to advance cancer treatment. Together we are taking cancer treatment to new levels and enabling truly patient-centered care.”

    About Princess Margaret Cancer Centre

    The Princess Margaret is a comprehensive cancer center with over 17000 new patients per year and over 3,000 staff. Its 850,000 square feet house 202 in-patient beds, over 416,000 square feet of research space and 17 radiation treatment machines on a single site, making it one of the largest comprehensive cancer treatment facilities in the world and the largest radiation treatment center in Canada. Through ongoing research, education and innovation, Princess Margaret continues to be on the frontiers of medical, surgical and radiation oncology, embracing the latest technology and international best-practices and setting standards for patient care.

    About RayCare

    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    Peter Thysell, CFO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)70 661 05 59

    peter.thysell@raysearchlabs.com

    PDF

    New RayCare and RayStation releases on show at AAPM

    PDF

    During 29 July–1 August, RaySearch will exhibit its latest advances at the 60th AAPM Annual Meeting in Nashville, US. The company will demonstrate RayCare 2A, the latest release of the groundbreaking oncology information system, and RayStation 8A, the new release of the innovative treatment planning system. The latest developments in machine learning technology* and online adaptive therapy will also be on show. Attendees are welcome to visit RaySearch at booth #321, and demonstrations can be booked now at: www.raysearchlabs.com.

    RayStation 8A 

    The new RayStation 8A release brings a broad range of advances, including full planning capabilities for the TomoTherapy®* and Radixact® Systems from Accuray. RayStation now supports the TomoDirect™ delivery mode in addition to TomoHelical™. Other developments in RayStation 8A include support for TomoTherapy in Plan Explorer, improvements for proton and carbon ion* therapy and further integration with RayCare®, the next-generation oncology information system. All TomoTherapy and Radixact users now have access to advanced RayStation features, including multi-criteria optimization (MCO), adaptive planning and Plan Explorer. Demonstrations can be booked by visiting RaySearch's and Accuray's respective booths.

    Improvements for proton and carbon ion therapy include automatic selection of range shifter for PBS machines and DICOM export of magnets in the lateral spreading device sequence for all ion treatment machines. Ion beam commissioning tools have also been refined for easier use, and carbon ion treatment machines are now supported in RayStation’s physics module. 

    RayCare 2A 

    New features and a range of general system enhancements from the newly released RayCare 2A will be demonstrated. The system now incorporates RayPACS, (picture archiving communication system), that makes it fast and easy to retrieve and share images. This unique managed PACS system makes it possible to tag images for efficient workflow automation. RayPACS can be used within RayCare or as a standalone PACS.

    Other new features include task-based and rule-based scheduling, including calendar views and schedules for all clinic resources, and charge capture, a tool for automatically capturing and managing billable codes from tasks performed in the workflow.

    VIP-tour at Provision

    During the AAPM conference, Provision Healthcare and RaySearch will together arrange an exclusive tour at the Provision Cares Proton Therapy Center in Nashville. The center is equipped with the latest technology within proton therapy, using the ProNova SC360 Proton system, RayCare and RayStation for all the treatment planning, enabling an integrated oncology approach and a seamless workflow experience.

    The tour will give insights in the vision for the new center, as well as how Provision partnered with RaySearch in the development of RayCare.

    Evening Symposium: Advancing cancer care through software innovation

    On Sunday 29 July, 6:30 pm-12:00am, RaySearch will hold an evening symposium focusing on advancing cancer care through software innovation. Location: Hermitage hotel, 231 6th Ave N, Nashville.

    6.30 pm

    Welcome reception

    7.30 pm - 7.35 pm

    Welcome by the moderator, Marc Mlyn, President of RaySearch Americas.

    7.35 pm - 7.55 pm

    Automatic treatment planning and machine learning from a clinical perspective

    Tom Purdie, Ph.D., Medical Physicist, Princess Margaret Cancer Centre, Toronto, Canada.

    7.55 pm - 8.35 pm

    Fight cancer with code

    Johan Löf, CEO, RaySearch Laboratories (publ), Stockholm, Sweden.

    8.35 pm

    Dinner buffet

    About RayCare

    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    Peter Thysell, CFO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)70 661 05 59

    peter.thysell@raysearchlabs.com

    PDF

    RaySearch has been awarded a major tender for treatment planning system in Quebec, Canada

    PDF

    RayStation has been chosen as the primary treatment planning system through a tender process, replacing the current treatment planning systems at the Centre intégré universitaire de santé et de services sociaux de l'Estrie-Centre hospitalier universitaire de Sherbrooke, in Quebec, Canada. The center treats approximately 2000 cancer patients a year and is equipped with 4 linear accelerators.

    RayStation was selected as the primary treatment planning system replacing their current system. The decision was motivated by RayStation’s outstanding functionality, such as scripting, multi-criteria optimization, streamlined adaptive therapy and automation. The purchase contains of a wide array of modules including multi-criteria optimization, Plan Explorer, AutoBreast planning and full support for adaptive radiotherapy. The full installation supports approximately 20 simultaneous users.

    Charles Lavoie, Coordinator of the Medical Physics group, says: “We are pleased that, through the tender process, we have found a treatment planning system that will satisfy our needs. RayStation will provide all of the latest technologies, and in addition help our department to be efficient. We look forward to implementing this system clinically.”

    Johan Löf, CEO of RaySearch, says: “We are pleased to have won another important tender with RayStation in Canada, and satisfied to have been able to meet all demands from the highly recognized clinic, Centre intégré universitaire de santé et de services sociaux de l'Estrie-Centre hospitalier universitaire de Sherbrooke. We look forward to see how our collaboration will evolve.

    The majority of this order has been delivered and will generate revenue in the second quarter of 2018.

    About Centre intégré universitaire de santé et de services sociaux de l'Estrie-Centre hospitalier universitaire de Sherbrooke

    The center is treating approximately 2000 patients a year and counts more than 17,000 employees including more than 1,000 physicians. It serves a territory spreading from Lac-Mégantic to Ange-Gardien comprising a population of more than 500,000 inhabitants.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    Peter Thysell, CFO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)70 661 05 59

    peter.thysell@raysearchlabs.com

    PDF

    RaySearch releases new version of the RayCare OIS

    PDF

    RaySearch has released RayCare 2A, the latest version of its groundbreaking oncology information system (OIS). RayCare is designed to support the workflow in a modern oncology center, connecting the different oncology disciplines, boosting efficiency and ensuring optimal use of resources.

    RayCare is developing rapidly with clinical input from leading cancer centers worldwide. The first clinical version of RayCare was released in December 2017, and Iridium Cancer Network in Belgium started using it clinically after only two months. RayCare 2A introduces new features and a range of general system enhancements.

    New features include task-based and rule-based scheduling for all clinic resources, management of clinical documents and forms connected to task management, and additional treatment management functions. RayCare’s advanced workflow capabilities have been further enhanced to enable customization of the individual patient's workflow, as well as automatic capture and management of billable codes from tasks performed in the workflow.

    RayCare 2A also incorporates RayPACS, a unique managed PACS (picture archiving and communication system) that makes it fast and easy to retrieve and share images. RayPACS is fully integrated with the RayCare workflow management system, enabling automated imaging workflows. All DICOM and non-DICOM objects relevant for radiation oncology can be stored, and rules for DICOM routing can be set up easily based on any DICOM tag.

    Johan Löf, CEO of RaySearch, says: “This latest release of RayCare takes important steps toward the goal of an OIS that supports and connects oncology workflows, and raises automation to new levels. By combining our technical innovation with the expertise of our clinical partners, we are redefining what is possible with an OIS.”

    About RayCare

    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    Peter Thysell, CFO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)70 661 05 59

    peter.thysell@raysearchlabs.com 

    PDF

    CHU de Québec-Université Laval in Canada has selected RayStation in combination with Varian’s TrueBeam linacs

    PDF

    Following a call for tenders from the CHU de Québec–Université Laval (CHU), RayStation has been designated as the treatment planning system for external beam planning at the new state-of-the-art cancer center, which will be located in the center of Quebec City. CHU is the largest university hospital groups in Quebec, providing general and specialized care for around 2 million people.

    The new cancer center will be equipped with seven Varian TrueBeam linacs, as well as advanced imaging systems such as CT Sim, MR Sim and PET CT. Four open vaults have been dedicated for stereotactic and adaptive radiation therapy. The majority of this order has been delivered and generated revenue in the first quarter of 2018. The order was also part of the announcement on March 31, 2018, read more here.

    RayStation was selected for its adaptive re-planning and automation capabilities, as well as the flexibility to include additional treatment machines in future expansions. Treatment planning integration, high speed and outstanding efficiency were also key factors.

    The comprehensive order further includes advanced RayStation features such as deformable registration, dose tracking, multi-criteria optimization, automated breast planning, Plan Explorer and biological optimization. The center will have licenses for 85 simultaneous users, including treatment planners, physicists, radiation oncologists, therapists, simulation therapists and administrators. The center expects to treat their first patients with RayStation in December 2020.

    Johan Löf, CEO of RaySearch, says: “This highly advanced center is an excellent match for RayStation, which supports the most cutting-edge techniques and a broad spectrum of treatment machines. The choice made by CHU truly highlights the importance of an independent evaluation and selection of the treatment planning system and the machines. I am fully convinced that this is the future for radiation therapy centers. This is a major order for RaySearch and I look forward to a successful partnership.”

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    PDF

    Emory Proton Therapy Center in Atlanta has selected RayStation in combination with Varian’s ProBeam proton system

    PDF

    During March 2018, RayStation was selected as treatment planning system for Emory Proton Therapy Center, owned and operated by Provident Resources Group Inc. The new facility is currently under construction in Atlanta, Georgia, and is scheduled to treat its first patients in late 2018. Motivating factors for the choice include advanced functionality such as Monte Carlo dose optimization, 4D optimization, and multi-criteria robust optimization.

    The comprehensive RayStation installation includes VMAT, pencil beam scanning, multi-criteria optimization, biological optimization, fallback planning, deformable registration, dose tracking, adaptive replanning and contouring. The majority of this order has been delivered and generated revenue in the first quarter of 2018. The order was also part of the announcement on March 31, 2018, read more here

    When operational, Emory Proton Therapy Center and its clinical partners, The Emory Clinic and Emory Healthcare, will have the capacity to treat approximately 1800 patients per year, in five treatment rooms equipped with Varian’s ProBeam proton system. The technology on hand will include pencil beam scanning and intensity modulated proton therapy, as well as a robotic positioning system and advanced imaging technology such as on-gantry cone beam CT volumetric imaging. The center will also be an international leader in proton therapy research.  

    Mark McDonald, Medical Director, Emory Proton Therapy Center, says: “Our team selected RayStation because of its advanced treatment planning functions relevant to proton therapy, including Monte Carlo dose optimization, 4D optimization, and multi-criteria optimization.  We believe these features are critical to the development of high-quality and safe treatment plans that can extend the advantages of proton therapy to patients with a wider array of diagnoses. We look forward to continued collaboration with RaySearch as an excellent and innovative partner in proton treatment planning.”

    Johan Löf, CEO of RaySearch, says: “The leading functionality of RayStation is a very good match for Emory Proton Therapy Center, which will be a pioneering center for proton therapy and clinical research. Proton therapy is a key focus area for RaySearch, and we are constantly evolving our capabilities to include advanced features, such as Monte Carlo, to meet the needs of world leading centers. We are confident of a successful collaboration that will benefit many patients in Georgia.”

    About Emory Proton Therapy Center

    The Emory Proton Therapy Center combines the world’s most advanced radiation technologies and treatment with the expertise of renowned specialists from Winship Cancer Institute of Emory University, Georgia’s National Cancer Institute-designated comprehensive cancer center. When it opens in late 2018, the Emory Proton Therapy Center will be the first center of its kind in Georgia and one of only a few in the southeast US to offer patients access to this leading-edge type of radiation therapy. Winship Cancer Institute is at the forefront of cancer research and discovery, developing and delivering some of the world’s most effective ways to prevent, detect, diagnose, and treat cancer. 

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    PDF

    RayStation order from Heidelberg University Hospital in Germany strenghtens the existing partnership

    PDF

    Heidelberg University Hospital has placed an order for additional RayStation systems for photon beam therapy. This order is in line with the hospital’s ambition to have RayStation as its sole treatment planning system, replacing numerous existing systems.

    In april this year RayStation was selected for particle therapy jointly by clinicians and researchers at Heidelberg Ion Beam Therapy Center (HIT) and Marburg Ion Beam Therapy Center (MIT), Heidelberg University Hospital and the German Cancer Research Center (DKFZ). Now RayStation has also been selected for conventional photon beam therapy.

    The order will strenghten RaySearch’s existing collaboration with Heidelberg University Hospital and the partnership to pioneer the RayCare™* oncology information system (OIS). The RayStation order will connect Heidelberg University Hospital, HIT, MIT, DKFZ and a satellite clinic in Weinheim close to Heidelberg. The system will be used across all centers.

    The decision was motivated by RayStation’s outstanding functionality and comprehensive support for the ion treatment technique*, as well as its capacity to plan for photon linacs and Accuray’s TomoTherapy delivery system on the same software platform.

    Prof. Jürgen Debus, Chairman of the Radiation Therapy department at Heidelberg University Hospital, says: "We are fascinated by the new opportunities in RaySearch’s treatment planning, which will seamlessly integrate all modern technologies in Heidelberg, like protons, heavy ions, Cyberknife and TomoTherapy, with standard VMAT-treatments."

    Johan Löf, CEO of RaySearch, says: "I'm very pleased to strenghten our relationship with Heidelberg University Hospital. It is satisfying to see that RayStation meets the demands of one of the top university hospitals in Germany."

    The systems included in this order have been delivered and will generate revenue in the second quarter of 2018.

    About Heidelberg University Hospital
    Heidelberg University is the oldest university in Germany; its first medical lectures were held here in 1388. Today, Heidelberg University Hospital is one of the largest and most prestigious medical centers in Europe, with a reputation based on excellent patient care, research and teaching. Heidelberg University Hospital offers inpatients and outpatients an innovative and effective diagnosis and therapy for all complex diseases. Modern buildings with state-of-the-art equipment delivers medical care to the highest international standards. The proximity and interlinking of the specialist departments benefit the patient, with interdisciplinary cooperation ensuring optimal treatment.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    PDF

    Advanced Oncotherapy (AVO) selects RayStation for the first LIGHT System in central London

    PDF

    The UK based developer of next generation proton therapy technology, Advanced Oncotherapy plc (AVO), has selected RayStation as its treatment planning system for the first LIGHT (Linac Image Guided Hadron Technology) system at the proton therapy facility under construction at Harley Street in central London. Users at the clinic will have access to the full spectrum of RayStation’s functionality.

    AVO and RaySearch have entered into a collaboration agreement to support the LIGHT system fully. The LIGHT system is a modular proton therapy system based on innovative technology, developed in a collaboration between the TERA project and CERN in Geneva, Switzerland. The heart of the system consists of a treatment room integrated with a linear accelerator, which accelerates protons to energies suitable for radiation therapy of cancer. The entire system is designed for cost effectiveness and low maintenance and has several key features, such as multiple spot sizes and fast energy switching time.

    The order of RayStation for Harley street gives the users access to the full spectrum of RayStation's functionality, including the fast proton Monte Carlo dose engine, robust 4D optimization, LET driven optimization, deformable registration, dose accumulation, plan adaptation, multi-criteria optimization and Plan Explorer for automatic plan generation.

    Nicolas Serandour, AVO Chief Executive Officer, says: “We are thrilled to collaborate with RaySearch. RaySearch has established themselves as the technology of choice for light ion therapy treatment planning. As we bring our advanced particle therapy treatment technology into the field, it makes sense to have the most advanced treatment planning capability to complement it. We believe the synergetic combination is significant for optimizing patient care at our first proton therapy center in the renowned medical practice area of Harley Street, London.”

    Dr Jonathan Farr, AVO’s Director of Medical Physics, says “Our linac based LIGHT system includes many special features requiring new treatment planning development and customization. RaySearch is uniquely poised to perform this and intends to deliver updates to their RayStation product supporting LIGHT advanced capabilities – thereby extending the accuracy and versatility of proton therapy.” 

    Johan Löf, CEO RaySearch, says: "AVO’s LIGHT system is a state-of-the-art solution for proton therapy, and we are very pleased that the RayStation treatment planning system was chosen by AVO. The LIGHT system has several advanced capabilities and RayStation will fully support this groundbreaking innovation. This new collaboration is in line with RaySearch’s ambition to provide full planning support for most treatment delivery machines on the market. The possibility to plan all types of radiation treatments on one common platform allows clinicians to select the optimal treatment machine and delivery technique for every patient, which in turn leads to better treatment quality and more effective use of available resources."

    The majority of this order has been delivered and will generate revenue in the second quarter of 2018. The remaining order value will generate revenue during the coming 36 months.

    About Advanced Oncotherapy 

    Advanced Oncotherapy plc (AVO) is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team Applications of Detectors and Accelerators to Medicine (ADAM SA), based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control. Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as lower treatment-related side effects. Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. For more information go to: www.avoplc.com

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    PDF

    Wake Forest Baptist Health in the US significantly extends its RayStation installation

    PDF

    The Comprehensive Cancer Center at Wake Forest Baptist Health in Winston-Salem, North Carolina, US, has placed an order for additional RayStation treatment planning systems, thereby significantly extending its existing installation. Going forward, RayStation will be the center’s primary treatment planning system.  

    The Comprehensive Cancer Center at Wake Forest Baptist Health, one of only 47 cancer centers in the US designated as comprehensive by the National Cancer Institute (NCI), has a long history of providing the best cancer care available, including radiation therapy, chemotherapy and surgery.

    The RayStation order comprises a broad range of functionality, including planning support for IMRT, VMAT and advanced functionalities such as multi-criteria optimization and deformable registration.  

    Johan Löf, CEO of RaySearch, says: "We are very pleased to meet the needs of the highly considered Wake Forest Baptist Health, who provide world-class cancer care. Comprehensive cancer care is what RaySearch strive for and we look forward to the extended collaboration and to see what we can achieve together with Wake Forest Baptist Health.”

    The systems of this order have been delivered and is will generate revenue in the second quarter of 2018.

    About Comprehensive Cancer Center at Wake Forest Baptist

    The Comprehensive Cancer Center has a long history of providing the best cancer care available, in a caring and compassionate manner. Wake Forest Baptist has proudly held the NCI designation since 1974 and NCI comprehensive designation since 1990, ensuring that all patients have access to the latest treatments, technologies and clinical trials.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    PDF

    Kobe Proton Center now clinical with RayStation

    PDF

    Kobe Proton Center in Japan has recently started clinical application of RayStation 7 for treatment. The first patient was treated in March 2018 using the uniform scanning method with a plan created in RayStation.

    The new state-of-the-art center opened in 2017 and was one of the first clinical installations for particle therapy for RayStation in Japan. The RayStation system has been adapted to Mitsubishi Electric Corporation's special PBS delivery techniques. The order was placed in 2016, and the adaptation was successfully validated last year in partnership with Mitsubishi Electric Corporation.

    Kobe Proton Center is equipped with Mitsubishi Electric Corporation’s new multifunction irradiation nozzle, which can be used in uniform scanning or PBS mode and is capable of quickly switching between the two modes. The new technology includes a high dose rate beam delivery system that reduces irradiation time by 75 percent for improved patient comfort. Currently, the system is being used in uniform scanning mode, and PBS will be introduced in the near future.

    Tomohiro Yamashita, Medical Physicist at Kobe Proton Center, says: "Our important mission is to provide the best proton therapy possible to pediatric patients with cancer. To achieve the goal, we need the most advanced technology present and we are happy that RayStation 7 gives us opportunities to apply many advanced functionalities with efficiency. We hope RaySearch will continue to be a leading company in the area of proton therapy and enable us to provide the best care to pediatric patients."

    Johan Löf, CEO of RaySearch, says: "We are very pleased to see the first patient treatment with RayStation treatment plan at Kobe Proton Center. Proton therapy is a special focus area for RaySearch and Japan is one of the world’s most technologically advanced markets. We have a strong user base in Japan and are strengthening our presence to support the market more fully. I look forward to a successful cooperation with Kobe Proton Center."

    About Kobe Proton Center

    Kobe Proton Center is a branch center of Hyogo Ion Beam Medical Center, which has a wealth of knowledge and experience of applying proton and Carbon-ion therapy to cancer patients. Kobe Proton Center was founded to leverage the experience and provide proton therapy to patients of all backgrounds and especially pediatric patients who would be extra benefited by the characteristic proton dose distribution. The center is thus located next to Hyogo Prefectural Kobe Children's Hospital and the two hospitals are in close cooperation.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    PDF

    Provision CARES Proton Therapy Center in Knoxville, Tennessee, US, treats first patients using RayStation and the new ProNova SC360 Proton System

    PDF

    Provision Healthcare, an industry- leading innovator in comprehensive, collaborative cancer solutions, has treated its first patients using RayStation in combination with Provision’s newly developed ProNova SC360 proton therapy system.

    This milestone establishes a new standard of excellence combined with the most advanced technology available in proton therapy and treatment planning. The procedures were executed successfully, and the RayStation plan performed seamlessly with the ProNova control system.

    In 2014, Provision became the first center in the world to use RayStation for clinical proton treatments.  The center provides advanced cancer treatment to patients locally, regionally and internationally. The Provision network has continued to push the boundaries of radiation therapy, when adding the ProNova SC360 proton system, and treating the first patient in February 2018. It now offers the latest in treatment technology, personalized medical practice and an innovative, integrative approach to comprehensive cancer care.

    Niek Schreuder, VP and Chief Medical Physicist, for Provision Healthcare, says: “We have used RayStation clinically for years, and we have been collaborating with RaySearch since the beginning of the development of the SC360. We are delighted that things have gone so well, and as we open new centers throughout the world, we expect to implement RayStation, RayCare* and the SC360 system together to assure seamless interoperability and dynamic workflows.”

    Johan Löf, CEO of RaySearch, says: “We are very pleased to support the Provision CARES Proton Therapy Network in achieving this treatment milestone with a state-of-the-art proton therapy solution. RayStation’s advanced capabilities are an excellent match for the center’s aims of increasing treatment precision and clinical efficiency. Together we are taking proton therapy forward for the benefit of cancer patients.”

    About Provision CARES Proton Therapy Network  

    The CARES Cancer Network is focused on providing the most comprehensive and advanced treatment options for patients. This network extends across the world and promotes collaborative care and research that benefits the patient and the larger fight against cancer. Provision CARES Proton Therapy Center in Knoxville is the first cancer treatment center of its kind in Tennessee. The center aims to provide personalized, comprehensive patient care with leading-edge technology, offering one of the most advanced non-invasive cancer treatments in the world.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

     

    PDF

    RaySearch and Eckert & Ziegler BEBIG enter into partnership regarding brachytherapy

    PDF

    RaySearch and Eckert & Ziegler BEBIG, a leading European supplier of brachytherapy products, have signed a partnership agreement. Both the RayStation® treatment planning system and the RayCare* oncology information system will be integrated* with the Eckert & Ziegler BEBIG brachytherapy systems. 

    This will allow Eckert & Ziegler BEBIG to offer a complete brachytherapy solution, including treatment devices, treatment planning and oncology information management. The cooperation is in line with RaySearch’s aim to support as many treatment systems and approaches as possible.

    Brachytherapy is a radiation therapy technique in which a small radioactive implant is inserted into the patient’s tissue, directly into the tumor or close to it. The implant may be temporary or permanent. Using implants makes it possible to deliver a higher dose of radiation to a smaller area than may possible with other forms of radiation therapy, thus minimizing damage to surrounding tissue and organs. Brachytherapy is most commonly used in treating prostate cancer but can be applied to many other areas, including cancers of the brain, eye, lung and skin.

    Dr. Harald Hasselmann, CEO of Eckert & Ziegler BEBIG, says: “We are very happy about the partnership with RaySearch, which promises a pathway to better integration of brachytherapy into modern radiation therapy workflows. Brachytherapy can significantly improve treatment outcome, either as a single treatment method or in combination with other therapies. Integration is key for future optimization, and this partnership is an important step forward.”

    Johan Löf, CEO of RaySearch, says: “It is exciting to enter into this new treatment area for RayStation and RayCare. Brachytherapy is a highly accurate technique, and the capabilities of our software will bring a new dimension to treatment. We have an excellent partner in Eckert & Ziegler BEBIG, a leading brachytherapy innovator with an excellent product portfolio, and I look forward to a successful collaboration.”

    About Eckert & Ziegler BEBIG 

    Eckert & Ziegler BEBIG is a global provider of radiotherapy products and a brachytherapy leader in Europe. The company has offices and subsidiaries are located in Belgium, Germany, France, Spain, UK, US, India and Brazil, as well as a worldwide network of distributors and agents. Eckert & Ziegler BEBIG is a young, dynamically growing company and employs approximately 145 people worldwide. The company has been listed on the Euronext stock exchange since April 1997.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RayCare

    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    PDF

    The Ottawa Hospital becomes the 500th customer for RayStation treatment planning system

    PDF

    The Ottawa Hospital has placed an order for RayStation, RaySearch’s innovative radiation therapy treatment planning system, becoming the 500th customer. Since the first sale in 2009, RaySearch has worked hard to ensure that RayStation remains the premier treatment planning system, covering the broadest range of treatment delivery machines and providing the most comprehensive functionality. The steadily growing user base is a testament to the confidence cancer centers have in the system.

    RayStation’s capabilities have evolved continuously through regular releases. The latest version, RayStation 8A*, includes full planning capabilities for Accuray TomoTherapy® systems, improvements for proton and carbon ion therapy and further integration with RayCare®*, the next-generation oncology information system.

    The system is appreciated worldwide for advanced functionality such as VMAT, deformable dose accumulation, atlas-based segmentation and Plan Explorer, a unique feature that makes it possible to generate a large number of treatment plans automatically. RayStation functionality will continue to advance at a steady pace to take patient outcomes and clinical efficiency even further.

    Dr. Jason Pantarotto, head of the Radiation Medicine Program at The Ottawa Hospital, says: “RayStation will complement our existing technology quite nicely, leading to efficiencies in treatment planning across multiple platforms. With almost 5000 courses of radiation delivered over multiple sites, efficiency is a key component to our care delivery model.”

    Johan Löf, CEO of RaySearch, says: “We are very happy that we are now bringing the benefits of RayStation to 500 customers worldwide. RayStation has proven itself to be the premier treatment planning system. We are looking forward to an exciting future as we take automation to new levels and deepen integration with RayCare, the next-generation oncology information system. This is truly just the beginning.”

    About The Ottawa Hospital

    The Ottawa Hospital is one of Canada’s largest learning and research hospitals with over 1,100 beds, approximately 12,000 staff and an annual budget of over $1.2 billion. Our focus on research and learning helps us develop new and innovative ways to treat patients and improve care. As a multi-campus hospital, affiliated with the University of Ottawa, we deliver specialized care to the Eastern Ontario region, but our techniques and research discoveries are adopted around the world. We engage the community at all levels to support our vision for better patient care.  

    About RayCare
    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    PDF

    Rabin Medical Center becomes first Israeli clinic to order RayStation

    PDF

    Rabin Medical Center (RMC) has selected RayStation for radiation therapy treatment planning at its Davidoff Cancer Center, located in Petah Tikva, Israel. This is the first order from a clinic in Israel, and the installation will include licenses for 3DCRT, IMRT, VMAT and adaptive therapy.

    Following an evaluation of the leading systems, RMC chose RayStation due to factors such as its fast and accurate dose calculation and outstanding adaptive therapy capabilities. The purchase was funded by a donation from a patient, Ms. Desiree Dagmi, who was treated by Professor Eyal Fenig at RMC. Ms. Dagmi wanted to show her gratitude through a contribution that would help the center provide an even better service to patients.

    Serving as a national center of excellence in cancer care prevention and research, RMC’s Davidoff Center is the most sophisticated and innovative facility in the Middle East for the treatment of malignant diseases, delivering comprehensive medical treatment to some 20 percent of the country’s oncology patients. The patient-friendly center integrates all of RMC’s inpatient and outpatient oncology services.

    Amineh Khatib Hamad, Medical Physicist at RMC, says: “Time is an important factor for a busy clinic such as Davidoff Cancer Center. RayStation is faster than any other system in computing dose with IMRT plans, and its algorithms provide more accurate determination of dose for homogeneities than our current system. RayStation allows the summation of previous treatments with current ones to provide a good representation of dose accumulation and constraints for organs at risk, which is something we are not currently able to do. It also has the most fluent workflow for adaptive radiotherapy; we treat more than 200 patients per day, and it’s important for us to ensure high standards of treatment while allowing adaptation of personalized plans in minimum time.”

    Johan Löf, CEO of RaySearch, says: “RMC is one of the leading clinical research centers in the Middle East and we are very pleased to meet their needs for high speed and accuracy. There is growing worldwide interest in adaptive therapy, and RayStation’s capabilities help make it clinical viable on a large scale.”

    About Rabin Medical Center (RMC) and Davidoff Center

    RMC is at the forefront of Israel's healthcare system. It was founded with the merger of two existing hospitals: Beilinson and Hasharon in Petah Tikva. RMC is a major tertiary referral center for patients from all over Israel and beyond and a prestigious teaching hospital affiliated with the Tel Aviv University Sackler School of Medicine. RMC has been acknowledged since its founding for setting new standards of medical care and for pioneering breakthroughs in technology and medical expertise. Davidoff Center’s multidisciplinary team has leading medical experts in all the essential fields, including renowned physicians and nurses who work together to develop the best individual therapy plan for each patient. Together they provide top-quality curative and palliative care, as well as conducting extensive research into new and innovative treatment options.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    PDF

    Tsuyama Chuo Proton Beam Center, Japan, treats first patients with RayStation

    PDF

    Tsuyama Chuo Hospital in Okayama Prefecture, southwest Japan, has commenced clinical use of RayStation to plan pencil beam scanning (PBS) treatments at its Proton Beam Cancer Center. On 15 May, the center carried out the world’s first patient treatment using RayStation together with Mitsubishi Electric’s proton therapy system, with a plan created in RayStation 6.

    The proton center opened in 2016 and is run jointly with Okayama University. It is equipped with Mitsubishi Electric’s proton therapy system, featuring the SELECTBEAM nozzle, which supports both PBS and uniform scanning (US). Tsuyama Chuo Hospital has also expressed an interest in starting PBS treatments using multi-leaf collimator (MLC), following market clearance of Mitsubishi Electric’s MLC technique by Japanese authorities.

    Yuki Tominaga, Medical Physicist at Tsuyama Chuo Proton Beam Center, says: "We are very pleased to have started PBS treatment safely using RayStation 6. In the future, we would like to establish comprehensive treatment combining PBS, US and photons with high-precision RayStation features such as multi-criteria optimization and deformable image registration."

    Johan Löf, CEO of RaySearch, says: “We are delighted by this first clinical treatment with RayStation at Tsuyama Chuo Hospital. Proton therapy is a key focus area for RaySearch, and our goal for RayStation is to support as many treatment delivery platforms as possible. I look forward to a long and successful clinical cooperation.”

    About Tsuyama Chuo Hospital

    The hospital opened in 1951 and was the first general hospital in northern Okayama Prefecture. The Proton Beam Cancer Center opened in 2016 and is jointly operated with Okayama University Hospital. Both organizations have central roles in proton beam therapy, clinical research and education at the new facility.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has recentley launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    PDF

    MedStar Georgetown University Hospital now clinical with RayStation and Hyperscan

    MedStar Georgetown University Hospital in Washington, D.C., has begun patient treatments using the RayStation treatment planning system in combination with Mevion’s Hyperscan pencil beam scanning system. This was the world’s first treatment carried out on the Mevion S250i Proton Therapy System®.

    The combination of RayStation and Mevion’s Hyperscan technology enables clinicians at MedStar Georgetown to plan and treat patients with the advantage of very sharp field edges and minimized radiation to critical structures.

    RayStation enables the use of advanced IMPT capabilities that are unique to the Hyperscan technology, including multi-leaf collimation with Mevion’s Adaptive Aperture, a proton multi-leaf collimator (pMLC) designed to achieve sharp lateral dose gradients and protect sensitive organs at every energy layer of the treatment.

    Johan Löf, CEO of RaySearch, says: “We are very pleased to see this groundbreaking patient treatment at MedStar Georgetown, using RayStation in combination with Mevion’s Hyperscan technology. Proton therapy is an important focus area and RaySearch is committed to supporting all the latest techniques and systems. Together we will ensure that more and more patients can benefit from this high-precision form of treatment.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    New RayStation 8A release adds support for TomoDirect Treatment Delivery

    RaySearch has announced the release of RayStation® 8A*, the latest version of its innovative radiation therapy treatment planning system. The new release brings a broad range of advances, including full planning capabilities for the TomoTherapy®* and Radixact systems from Accuray, and supports the TomoDirectTM delivery mode in addition to TomoHelicalTM. Other advances in RayStation 8A include support for TomoTherapy in Plan Explorer, improvements for proton and carbon ion therapy and further integration with RayCare*®, the next-generation oncology information system.  

    The release of RayStation 8A is one more step towards RaySearch’s goal of unifying treatment planning for as many treatment delivery systems as possible, eliminating the complications and additional steps that arise from using multiple software systems. All TomoTherapy and Radixact users now have access to advanced RayStation features, including multi-criteria optimization (MCO), adaptive planning and Plan Explorer.

    With the addition of Plan Explorer functionality, TomoTherapy and Radixact clinics can now automatically generate a large number of treatment plans for defined clinical goals and combinations of treatment techniques and machines, optimizing the use of treatment machines and increasing treatment planning efficiency.

    Improvements for proton and carbon ion therapy include automatic selection of range shifter for PBS machines and DICOM export of magnets in the lateral spreading device sequence for all ion treatment machines. Ion beam commissioning tools have also been refined for easier use, and carbon ion treatment machines are now supported in RayStation’s physics module.

    RayStation 8A strengthens integration with RayCare. Other general improvements include the possibility to choose independent isocenters and/or independent directions for robust optimization, the ability to view DVHs in absolute volume and an improved user interface for DICOM import.

    Johan Löf, CEO of RaySearch, says: “This latest RayStation release is an important step forward. We are very pleased to expand our support for the TomoTherapy platform, giving all users access to innovative RayStation features. We have also included some significant additional features for particle therapy, which is an important focus area for RaySearch. Many more exciting developments are in the pipeline for upcoming releases, and we will announce these in the near future.”

    About RayCare

    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    Resolutions at the annual general meeting 2018

    PDF

    At the Annual General Meeting of RaySearch Laboratories AB (publ) held on May 30, 2018, the following resolutions were adopted.

    It was resolved that the accumulated profit, amounting to SEK 211,283,000 be brought forward and balanced in the new accounts.

    The Annual General Meeting adopted the balance sheets and income statements and discharged the members of the Board and the CEO from personal liability.

    It was resolved to adopt the guidelines for remuneration to senior executives proposed by the Board, to apply until the close of the Annual General Meeting 2019.

    It was resolved that remuneration to Board members who are not on the pay-roll of any Group company will amount to, with respect of the Chairman, SEK 480,000, and SEK 250,000 to each of the other Board members.

    It was resolved that the Auditor’s fees be paid in accordance with current approved invoicing.

    It was resolved to re-elect Carl Filip Bergendal, Johan Löf, Hans Wigzell and Johanna Öberg as Board members of the company, to elect Britta Wallgren as new board member and to appoint Carl Filip Bergendal as Chairman of the Board.

    It was resolved to re-elect the auditing firm Ernst & Young as Auditors, with the authorized public accountant Per Hedström as auditor in charge.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003. For more information about RaySearch, visit www.raysearchlabs.com.

    * Subject to regulatory clearance in some markets. 

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    PDF

    RaySearch and NIRS/QST, Japan, enter into collaboration agreement regarding ion beam therapy

    PDF

    RaySearch has signed a research collaboration and licensing agreement with the National Institutes for Quantum and Radiological Science and Technology (QST), a pioneer of ion beam technology based in Chiba, Japan. QST was established in 2016 when the National Institute of Radiological Sciences (NIRS) was merged with certain functions of the Japan Atomic Energy Agency.

    The research collaboration agreement will focus on advancing ion beam therapy via the pencil beam scanning technique. Researchers from RaySearch and NIRS will explore areas such as biological modeling of ion-beam irradiation and dose fractionation, robust beam delivery and plan optimization algorithms. The partnership includes a long-term licensing agreement that enables RaySearch to integrate the microdosimetric kinetic model (MKM) developed at NIRS, into the RayStation treatment planning system.  

    Ion beam therapy is a highly advanced form of radiation therapy in which tumors are treated with protons or heavier ions such as helium or carbon. NIRS pioneered the clinical application of ion beam therapy during the 1990s, and the development of its MKM for calculating dose during treatment plan optimization was an important step forward.

    Users will be able to combine the new functionality with existing features for carbon pencil beam scanning, such as robust 4D biological optimization, deformable registration, dose tracking and adaptive therapy. The MKM will be available in clinical releases of RayStation later this year*.

    Koji Noda, Director general of NIRS, says: This collaboration agreement with RaySearch is important for the global advancement of ion beam therapy. Together we will take the technology forward to improve treatment for patients worldwide. 

    Johan Löf, CEO RaySearch, says: “NIRS is a world leader in the development of technologies for ion beam therapy and RaySearch is the leader in advanced cancer treatment software. We are very excited about this collaboration and the clinical benefits that will result from integrating the technology in RayStation.”

    About NIRS, QST

    NIRS was founded in 1957 with a mission to advance basic and applied research into radiological science in Japan. In the decades since, the mission has been conducted in terms of "aggressive" and "passive" applications of radiation. Aggressive applications include imaging of biological change at the molecular level and cancer treatment with high-energy ion beams. Passive research is oriented towards clarifying the biological consequences of radiation and preventing any adverse effects, as well as training and educating future research professionals in the field. QST was formed in April 2016 when NIRS merged with the quantum beam and nuclear fusion departments formerly belonging to the Japan Atomic Energy Agency.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    PDF

    Strong uptake of RayStation Monte Carlo dose engine among proton therapy centers

    PDF

    13 out of 18 RayStation proton sites in clinical operation are now using the proton Monte Carlo (MC) dose engine, and this just a year after it was released. That according to a survey. “The implementation of the RayStation Monte Carlo dose engine has expanded our capability to serve more and a wider range of patients”, says Chang Chang, Director of Physics, Texas Center for Proton Therapy.

    One year after RaySearch's first release of the proton MC dose engine in RayStation 6, a survey was sent out to the 18 RayStation proton sites that are in clinical operation with pencil beam scanning. The survey focused on the clinical implementation and use of the new MC dose engine. The answers showed that no less than 13 of the 18 clinics have implemented the MC dose engine in their clinical work flows, with remaining clinics currently in commissioning. Several clinics report that they use the MC dose engine for all patients, while others use it for selected cases where high accuracy is important, such as lung, brain, breast or head and neck.

    Peer reviewed research papers are being published showing that Monte Carlo is now considered key for certain cancer types, which has prompted rapid implementation and acceptance. One prime example is “Pencil Beam Algorithms Are Unsuitable for Proton Dose Calculations in Lung”[1] .

    Significantly, all clinics that have adopted MC for final dose computation, state that they also use it to drive the optimization. No significant deviations in the clinics validation studies have been reported. Also, all clinics mention very good results in the patient specific QA, especially for fields that employ a range shifter as compared to the results with the analytical dose engine.

    Chang Chang, Director of Physics, Texas Center for Proton Therapy says: “The implementation of the RayStation Monte Carlo dose engine has expanded our capability to serve more and a wider range of patients. For example, it enabled us to use larger range shifter to patient air gaps, which streamlined our process in the treatment rooms. In addition, the higher accuracy of the Monte Carlo dose engine allowed us to treat sites like lung, complicated head and neck, and breast with more confidence."

    Xavier Vermeren, Chief physicist, West German Proton Therapy Centre Essen says: “Now, when we find a rare deviation in our patient specific QA, we always double check our QA setup and data first. We simply expect the RayStation Monte Carlo dose to be correct, and we have yet to see a field that fails the QA."

    Johan Löf, CEO of RaySearch, says: “We are extremely pleased to see that such a high fraction of our customers has implemented the Monte Carlo dose engine in a relative short time. It is also highly rewarding to learn how this new product has increased the quality of the treatments, while at the same time saving time for the physicists thanks to the improved QA results."

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 


    [1] Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):750-756. doi: 10.1016/j.ijrobp.2017.06.003. Epub 2017 Jun 13 

    PDF

    Latest RaySearch proton innovations to be showcased at PTCOG 57

    PDF

    During 21-25 May, RaySearch will exhibit at the PTCOG57 congress in Cincinnati, US, and demonstrate the latest proton news in RayStation. RaySearch will also show the latest updates in the next generation oncology information system, RayCare™. Attendees, welcome to visit RaySearch at booth #P2, and don’t forget to book a demo at www.raysearchlabs.com.  

    Key proton features in RayStation

    RaySearch is proud to be a world leader in proton therapy software, with well received proton features in RayStation, such as the fast Monte Carlo (MC) dose engine for PBS. A newly conducted survey shows that, only a year after the release, 13 of the 18 RayStation proton sites in clinical operation are using the proton MC dose engine.

    RayStation’s renowned proton features on display at PTCOG 57 will include our pioneering 4D robust optimization, adaptive re-planning, PBS planning with apertures and interplay evaluation. News for RayStation 7 include multi-criteria optimization (MCO) with robust constraints, and simulated organ motion. We will also demonstrate LET-based pencil beam scanning optimization, a feature currently in research, but scheduled for a coming release.

    RaySearch will demonstrate RayStation’s leading features for carbon ion beam therapy and new functionality including robust optimization, dose tracking and adaptive re-planning tools.

    Productive partnerships  

    RaySearch will also demonstrate the results of its commercial partnership with IBA and online adaptive proton therapy workflows that integrate RayStation, RayCare and IBA’s Adapt Deliver application. In this type of workflow, daily cone beam CT images are taken and matched to the planning CT for the patient. Based on the daily images, an updated treatment plan can be automatically suggested during a treatment session. A plan adaptation that takes the patient’s current situation into account can thus be made before treatment delivery starts. This workflow benefits patients by allowing for more accurate treatments and faster plan adaptation.

    Planning for Mevion’s Hyperscan technology will be on display as well, which is an outcome of the ongoing collaboration between RaySearch and Mevion.

    These developments are in line with RaySearch’s strong ambition to unify treatment planning for as many systems as possible, eliminating the complications and additional steps that arise from using multiple software systems.

    RayCare news

    RayCare 1 was launched in December 2017 and is already in clinical use at Iridium Cancer Network in Belgium. Development of upcoming versions of RayCare* is going forward rapidly. RaySearch will demonstrate the latest improvements and features at PTGOG 57, like advanced workflow management tools and integrated planning workflow support for RayStation. RayCare’s digital workflows are highly configurable and the task management features enable an integrated planning experience with RayStation, supporting automation of protocol steps and communication around planning tasks.

    Other features on show will include the built-in PACS system, which supports automation of imaging workflows, and the control room client for radiation therapy treatment management.

    Lunch symposium: Advancing Radiation Therapy Through Software Innovation

    On Friday 25 May, 11:30-12:30pm, RaySearch will hold a lunch symposium focusing on advancing radiation therapy through software innovation. Location: Grand Ballroom. Moderator will be Marc Mlyn, President of RaySearch Americas Inc.

    11:30 - 11:45 Welcome

    Moderator Marc Mlyn, President RaySearch Americas, Inc., New York, USA.

    11:45 - 12:05 A comprehensive approach to lung treatment with 4D-robust optimization and MC dose calculation in RayStation
    Chang Chang, Ph.D, D.A.B.R., Director of Physics, Texas Center for Proton Therapy, US.

    12:05 - 12:25 The sharper edge: Clinical benefits of aperture-based PBS

    Vinai Gondi, MD, Director of Research & Education, Northwestern Medicine Chicago Proton Center, US.

    12:25-12:30 Questions and answers

    About RayCare

    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com 

    PDF

    Interim Report January 1 – March 31, 2018

    PDF

    RaySearch Laboratories AB (publ)

    “During the first quarter 2018, net sales decreased 8 percent to SEK 116 M (127) and operating margin declined to 12 percent (26), primarily due to changes in accounting policies. With unchanged accounting policies, net sales would have been the same as the corresponding quarter of 2017, i.e., SEK 127 M, and the operating margin 19 percent. Cash flow before financing activities improved to SEK 13 M (8). We are secure in our long-term strategy and our expansion is continuing,” says Johan Löf, CEO of RaySearch.
       
     

    THREE MONTHS (JANUARY-MARCH 2018)

    • Net sales SEK 116.3 M (126.8), of which revenues from RayStation/RayCare SEK 104.2 M (112.3)
    • Profit after tax SEK 11.8 M (26.3), and earnings per share before/after dilution SEK 0.34 (0.77) 
    • Operating profit SEK 14.1 M (33.5) 
    • Cash flow for the period SEK 12.3 M (neg: 3.0) 
    • Order intake excl. service agreements SEK 106.6 M (104.9), of which RayStation/RayCare SEK 97.4 M (93.8) 
    • At the end of the period, the order backlog excl. service agreements for RayStation/RayCare was SEK 58.5 M (58.1)
        

    CHANGES TO ACCOUNTING POLICIES 

    • IFRS 15 Revenue from Contracts with Customers applies as of January 1, 2018, which has reduced the company’s license revenue from RayStation by 12.5 percent during the first quarter 2018 compared with previous accounting policy (IAS 18), see Notes 1-2. The changed accounting policies also have a negative impact on net sales and earnings in the last 12-months period.
         

    SIGNIFICANT EVENTS DURING THE FIRST QUARTER 

    • RayStation was selected by several leading cancer centers, including Georgia Proton Treatment Center and Mission Hospital – SECU Cancer Center in the US, CHU de Québec-Université Laval in Canada, and Universitätsmedizin Rostock and Klinikum rechts der Isar der TU München in Germany. 
    • RaySearch entered into a strategic partnership with MD Anderson with intention of improving radiation therapy.
    • In March 2018, 200,000 Class A shares were converted to Class B at the request of a shareholder.
         

    SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

    • RayStation has been selected as the treatment planning system for the two proton and carbon ion therapy centers, Heidelberg Ion Beam Therapy Center (HIT) and Marburg Ion Beam Therapy Center (MIT), in Germany. 
    • RaySearch has entered into a long-term collaborative agreement for RayCare with Heidelberg University Hospital in Germany.
         

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on May 9, 2018 at 7:45 a.m. CET.
       

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO    Tel: +46 8 510 530 00    E-mail:
    johan.lof@raysearchlabs.com
    Peter Thysell, CFO    Tel: +46 70 661 05 59    E-mail:
    peter.thysell@raysearchlabs.com
        
     

    ABOUT RAYSEARCH
    RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which was launched in December 2017 and comprises a new product area for RaySearch. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at
    www.raysearchlabs.com.

    PDF

    Interim Report January 1 – March 31, 2018

    PDF

    RaySearch Laboratories AB (publ)

    “During the first quarter 2018, net sales decreased 8 percent to SEK 116 M (127) and operating margin declined to 12 percent (26), primarily due to changes in accounting policies. With unchanged accounting policies, net sales would have been the same as the corresponding quarter of 2017, i.e., SEK 127 M, and the operating margin 19 percent. Cash flow before financing activities improved to SEK 13 M (8). We are secure in our long-term strategy and our expansion is continuing,” says Johan Löf, CEO of RaySearch.
       
     

    THREE MONTHS (JANUARY-MARCH 2018)

    • Net sales SEK 116.3 M (126.8), of which revenues from RayStation/RayCare SEK 104.2 M (112.3)
    • Profit after tax SEK 11.8 M (26.3), and earnings per share before/after dilution SEK 0.34 (0.77) 
    • Operating profit SEK 14.1 M (33.5) 
    • Cash flow for the period SEK 12.3 M (neg: 3.0) 
    • Order intake excl. service agreements SEK 106.6 M (104.9), of which RayStation/RayCare SEK 97.4 M (93.8) 
    • At the end of the period, the order backlog excl. service agreements for RayStation/RayCare was SEK 58.5 M (58.1)
        

    CHANGES TO ACCOUNTING POLICIES 

    • IFRS 15 Revenue from Contracts with Customers applies as of January 1, 2018, which has reduced the company’s license revenue from RayStation by 12.5 percent during the first quarter 2018 compared with previous accounting policy (IAS 18), see Notes 1-2. The changed accounting policies also have a negative impact on net sales and earnings in the last 12-months period.
         

    SIGNIFICANT EVENTS DURING THE FIRST QUARTER 

    • RayStation was selected by several leading cancer centers, including Georgia Proton Treatment Center and Mission Hospital – SECU Cancer Center in the US, CHU de Québec-Université Laval in Canada, and Universitätsmedizin Rostock and Klinikum rechts der Isar der TU München in Germany. 
    • RaySearch entered into a strategic partnership with MD Anderson with intention of improving radiation therapy.
    • In March 2018, 200,000 Class A shares were converted to Class B at the request of a shareholder.
         

    SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

    • RayStation has been selected as the treatment planning system for the two proton and carbon ion therapy centers, Heidelberg Ion Beam Therapy Center (HIT) and Marburg Ion Beam Therapy Center (MIT), in Germany. 
    • RaySearch has entered into a long-term collaborative agreement for RayCare with Heidelberg University Hospital in Germany.
         

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on May 9, 2018 at 7:45 a.m. CET.
       

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO    Tel: +46 8 510 530 00    E-mail:
    johan.lof@raysearchlabs.com
    Peter Thysell, CFO    Tel: +46 70 661 05 59    E-mail:
    peter.thysell@raysearchlabs.com
        
     

    ABOUT RAYSEARCH
    RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which was launched in December 2017 and comprises a new product area for RaySearch. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at
    www.raysearchlabs.com. 

    PDF

    RaySearch publishes Annual Report 2017

    PDF

    For more information, please contact:
    Johan Löf, CEO                       Tel: +46 8 510 530 00          Email: johan.lof@raysearchlabs.com
    Peter Thysell, CFO               Tel: +46 70 661 0559           Email: peter.thysell@raysearchlabs.com

    PDF

    Invitation to Annual General Meeting 2018

    PDF

    The shareholders in RaySearch Laboratories AB (publ), corporate identity no. 556322-6157, are hereby invited to the Annual General Meeting, to be held on Wednesday, 30 May, 2018, at 6:00 p.m., at the company’s offices at Sveavägen 44, 7th floor, Stockholm, Sweden.

    RIGHT TO PARTICIPATE AND NOTICE 

    Shareholders who wish to participate in the Annual General Meeting and to have the right to vote, must:

    • be recorded in the share register maintained by Euroclear Sweden AB not later than Thursday, 24 May, 2018,

    • notify the company of their intention to participate in the Annual General Meeting by mail to RaySearch Laboratories AB (publ), P.O. Box 3297, 103 65 Stockholm, Sweden; by telephone +46 (0)8 510 530 00; by fax +46 (0)8 510 530 30; or by email to arsstamma2018@raysearchlabs.com, not later than Thursday, 24 May, 2018, at 4:00 p.m. Assistants may accompany shareholders to the Meeting only if the shareholder has provided notice of the number of assistants, a maximum of two, in the manner described above for notification of participation. Notification should include the shareholder’s name, personal or corporate identity number, shareholding, address and telephone number

    • at the Meeting be able to produce an ID-card valid in Sweden (e.g. passport, driver’s licence, national ID-card). Also, proxies and/or assistants must be able to produce an ID-card valid in Sweden (e.g. passport, driver’s license, national ID-card) as the case may be.

    Shareholders who have trustee-registered shares through a bank or broker, must request to temporarily register the shares in their own name with Euroclear Sweden AB to be entitled to exercise their voting rights at the Meeting. Such shareholders must inform the trustee of this request in adequate time prior to Thursday, 24 May, 2018, when such registration must have been completed.

    POWER OF ATTORNEY ETC.

    If a shareholder intends to be represented by proxy, the shareholder must issue a written power of attorney, duly dated and signed. For practical reasons, the power of attorney should be submitted to the company in advance. Please note, however, that the original of any power of attorney must be presented at the Meeting and that it is therefore not sufficient to send it by fax or email. A power of attorney template is available on the company’s website, www.raysearchlabs.com, and will be sent at no cost to shareholders who request it and provide their postal address or email address. A power of attorney is valid no longer than one year from its issuance, unless a longer period of validity is expressly stated; however, in no event longer than five years. Representatives of legal entities must present a copy of a registration certificate or corresponding authorization document that indicates the authorized signatory.

    PROPOSED AGENDA 

    1.  Opening of the Meeting.

    2.  Election of a chairman of the Meeting.

    3.  Preparation and approval of the list of shareholders entitled to vote at the Meeting.

    4.  Election of one or two minute-checkers.

    5.  Approval of the proposed agenda.

    6.  Determination whether the Meeting has been duly convened.

    7.  Address by the CEO.

    8.  Presentation of the Annual Report and the Auditors’ Report as well as the consolidated financial
         statements and the Auditors’ Report for the consolidated financial statements for the 2017 fiscal year.

    9.  Resolutions concerning

         a)  the adoption of the income statement and balance sheet and the consolidated income statement
              and consolidated balance sheet;

         b)  the disposition to be made of the company’s profits or losses as shown in the balance sheet
              adopted by the Meeting; and

         c)  the discharge of the members of the Board and of the CEO from personal liability.

    10.  Resolution on guidelines for remuneration to senior executives.

    11.  Determination of the number of members of the Board and deputies.

    12.  Determination of the fees to be paid to the Board and auditors.

    13.  Election of the members of the Board (including Chairman) and deputy member(s) of the Board.

    14.  Determination of the number of auditors and deputies.

    15.  Election of auditor.

    16.  Close of the Annual General Meeting.

    PROPOSED DECISIONS 

    Election of a chairman of the Meeting (item 2)

    Shareholders representing approximately 67 percent of the total number of votes in the company propose that Carl Filip Bergendal should be appointed chairman of the Meeting.

    Disposition of earnings (item 9 b)

    As the company is currently in a phase of rapid expansion that requires access to capital, the Board and the CEO propose that no dividend be paid to the company's shareholders. The accumulated profit of SEK 211,283,000 is proposed to be brought forward and balanced in the new accounts.

    Guidelines for remuneration to senior executives (item 10)

    The Board proposes the Meeting to adopt the following guidelines for remuneration to senior executives to apply for the period until the close of the Annual General Meeting of 2019.

    Salary and other remuneration

    The CEO shall receive a fixed salary and a variable remuneration. The variable remuneration shall amount to 2.0 per cent of the Group’s earnings before tax after allocations to the profit-sharing foundation RayFoundation, though not more than 12 months’ salary. In addition, the CEO may have other benefits of a common nature, such as a company car.

    The CEO’s salary shall be reviewed annually. This shall take place through negotiations between the CEO and the Chairman of the Board, after which the Chairman shall present a proposal to the other Board members. The CEO shall not be present when the Board discusses and resolves on this issue.

    The other senior executives are the Deputy CEO, Chief Financial Officer (CFO), Director of Research, Director of Development, Director of Sales and Marketing, Director of Sales for the Asia & Pacific region, Director of Service and the General Counsel. The other senior executives shall, as all other employees in RaySearch Laboratories AB (publ) except the CEO, be covered by the profit-sharing foundation RayFoundation, and thereby receive a variable remuneration. Furthermore, the following shall apply with regard to remuneration to the other senior executives.

    The Director of Sales and Marketing shall receive a fixed salary and a variable remuneration. The variable remuneration shall amount to a certain percentage of the sales of RayStation and RayCare worldwide.

    The Director of Sales for the Asia & Pacific region shall receive a fixed salary and a variable remuneration. The variable remuneration shall amount to a certain percentage of the sales of RayStation and RayCare in the Asia & Pacific region.

    The Deputy CEO, CFO, Director of Research, Director of Development, Director of Service, and the General Counsel, shall receive a fixed salary but no variable remuneration, other than being covered by the profit-sharing foundation RayFoundation in accordance with the above.

    The salaries of the other senior executives shall also be reviewed annually. This shall take place in negotiations between the CEO and each individual.

    Incentive programs

    There are no incentive programs intended specifically for senior executives and none is proposed. However, the senior executives, except the CEO, may participate together with the other employees in such option programs and profit-sharing programs as the company may apply.

    Pensions

    All pension undertakings are defined-contribution plans. The retirement age for the CEO and the other senior executives is 65 years and the pension premiums correspond to the Swedish ITP plan.

    Period of notice

    If the CEO terminates his employment, his period of notice is 6 months, and if the company terminates the CEO’s employment, the period of notice is 12 months. In both cases, the CEO is entitled to salary during the period of notice. In respect of the other senior executives there is a mutual period of notice of 3 months during which salary shall be paid.

    Severance pay

    Neither the CEO nor the other senior executives shall be entitled to any severance pay, in a formal sense, should their employment cease. However, as described above, the CEO and the other senior executives shall be entitled to salary during the period of notice.

    Deviation

    The Board proposes that the Board be entitled to deviate from the above guidelines if there are special reasons for such deviations.

    Number of members of the Board and deputies (item 11)

    Shareholders representing approximately 67 percent of the total number of votes in the company propose that the number of Board members be 5, with no deputies.

    Fees (item 12)

    Shareholders representing approximately 67 percent of the total number of votes in the company propose:

    that         remuneration to Board members who do not receive a salary from any Group company,
                   amount to a total of SEK 1,230,000 for the period extending to the next Annual General Meeting,
                   of which SEK 480,000 to be paid to the Chairman and SEK 250,000 to each of the Board members
                   elected by the Annual General Meeting.

    that         the auditors’ fees shall be paid in accordance with current approved invoicing. 

    Board, etc. (item 13)

    Shareholders representing approximately 67 percent of the total number of votes in the company propose:

    that         Carl Filip Bergendal, Johan Löf, Hans Wigzell and Johanna Öberg be
                   re-elected as Board members in the company;

    that         Britta Wallgren be elected as Board member in the company; and 

    that         Carl Filip Bergendal be elected as Chairman of the Board. 

    Determination of the number of auditors and deputies (item 14)

    Shareholders representing approximately 67 percent of the total number of votes in the company propose that there should be one auditor, with no deputies.

    Election of auditor (item 15)

    Shareholders representing approximately 67 percent of the total number of votes in the company together with the Board, propose that the auditing firm Ernst & Young be appointed as auditors, with the authorized public accountant Per Hedström as auditor in charge until the close of the Annual General Meeting of 2019.

    NUMBER OF SHARES AND VOTES AND INFORMATION ON HOLDING OF OWN SHARES 

    The total number of shares in the company at the date of this invitation is 34,282,773, of which 8,454,975 are Series A shares and 25,827,798 are Series B shares, which means that there are a total of 110,377,548 votes in the company. The company holds no own shares.

    AVAILABILITY OF DOCUMENTS AND OTHER ISSUES

    The Annual Report, the Auditor’s Report in accordance with Chapter 8, Section 54 of the Swedish Companies Act and the Board’s complete proposals in accordance with the above will be held available at the company’s offices and on the company’s website no later than from and including 9 May, 2018, and will be sent to those shareholders who have provided notice that they wish to receive such information from the company.

    THE RIGHT OF THE SHAREHOLDERS TO REQUEST INFORMATION

    The shareholders have the right at the Annual General Meeting to request that the Board and the CEO provide information about facts that can affect the assessment of an item on the agenda and facts that can affect the assessment of the economic situation of the company. Such information shall be provided if it can be done without substantial harm to the company. The obligation to inform also applies in respect of the company’s relationship to other Group companies, the consolidated financial statements and facts according to the above in respect of subsidiaries.

    *********

    Stockholm, April 2018

    PDF

    RaySearch partners with Heidelberg University Hospital on RayCare OIS

    Heidelberg University Hospital in Germany has entered into a partnership with RaySearch Laboratories AB (publ) to pioneer the RayCare™ oncology information system. The research partnership, which focuses on supporting comprehensive cancer care, will involve the hospital and the affiliated sites Heidelberg Ion Beam Therapy Center (HIT) and Marburg Ion Beam Therapy Center (MIT).

    Heidelberg University Hospital is a world-leader in clinical practice and advanced research in areas such as carbon ion and helium ion beam therapy and is working to establish the city of Heidelberg as a leading center for research.

    The innovative RayCare OIS is designed to support comprehensive cancer care. It integrates seamlessly with the RayStation® treatment planning system. But that’s just the start – RayCare will connect all the oncology disciplines, enabling users to fluidly coordinate tasks and ensure optimal use of resources.

    Over subsequent releases*, RayCare will evolve into a machine learning OIS with unique capabilities to coordinate oncology tasks, supporting comprehensive cancer care organized around each patient’s needs. This goal reflects the fact that many cancer patients receive a combination of treatment types, driving the need for combined workflows for radiation therapy, chemotherapy and surgery.

    Professor Jürgen Debus at Heidelburg University Hospital says: “We are proud to be integrated into the development process of RayCare. RayCare will improve workflow and quality in radiation oncology significantly.”

    Johan Löf, CEO of RaySearch, says: “The city of Heidelberg constitutes an extraordinary environment for innovation. In the field of oncology specifically, Heidelberg is home to the Heidelberg University, the University Hospital, the Ion Beam Therapy Center and even the German Cancer Research Center. Taken together, these institutions cover everything from basic research to translational research and clinical excellence. The first mission statement of RaySearch was to bring scientific advancements faster to the clinical world. We have since built a strong organization for research and development and brought two major software systems to clinics, RayStation and RayCare. The Heidelberg University Hospital and its affiliated sites are ideal partners to continue this development with, and I am proud that they have chosen to work with RaySearch to take comprehensive cancer care to the next level.”

    About Heidelberg University Hospital
    Heidelberg University is the oldest university in Germany; its first medical lectures were held here in 1388. Today, Heidelberg University Hospital is one of the largest and most prestigious medical centers in Europe, with a reputation based on excellent patient care, research and teaching. Heidelberg University Hospital offers inpatients and outpatients an innovative and effective diagnosis and therapy for all complex diseases. Modern buildings with state-of-the-art equipment delivers medical care to the highest international standards. The proximity and interlinking of the specialist departments benefit the patient, with interdisciplinary cooperation ensuring optimal treatment.

    About RayCare
    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation® treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare™, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.
      

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    Machine Learning and latest RayCare innovations on show at ESTRO 37

    PDF

    During 20–24 April, RaySearch will be exhibiting at the ESTRO 37 congress in Barcelona, Spain. In addition to the latest advances in machine learning technology* and online adaptive therapy, RaySearch will demonstrate the latest innovations in the groundbreaking RayCare™* oncology information system, which has now been released. RaySearch will also show the new features available in the latest release of its treatment planning system, RayStation®. Attendees are welcome to visit RaySearch at booth #1000, and demonstrations can be booked now at: www.raysearchlabs.com.

    New features in RayStation 7*
    New functionality and a wide range of general improvements will be on show. The latest RayStation release that will be demonstrated contains several enhancements to existing functionality that will contribute to improved workflows and planning efficiency, including integration with RayCare, the next-generation oncology information system. Major new functionality includes the addition of robust constraints in multi-criteria optimization (MCO), simulated organ motion for robust optimization and evaluation, multi-atlas-based segmentation and conformal arc planning for photons. 

    Significant additions on the proton side include support for Hyperscan™ pencil beam scanning technology from Mevion Medical Systems, and support for uniform scanning for proton therapy systems from Mitsubishi Electric. Other proton therapy improvements include snout rotation for passive proton techniques and MLC collimation for PBS and passive techniques. 

    RayCare: the next-generation oncology information system
    RayCare 1 was launched in December 2017 and is already in clinical use at Iridium Cancer Network in Belgium. Iridium will present its first experiences with the system during the RaySearch lunch symposium on Saturday 21 April.

    Development of upcoming versions of RayCare is going forward rapidly. RaySearch will demonstrate the latest improvements and features, including advanced workflow management tools and integrated planning workflow support for RayStation. RayCare active workflows are highly configurable and the task management features enable an integrated planning experience with RayStation, supporting automation of process steps and communication around planning tasks.

    Other features on show include the built-in PACS system, which supports automation of imaging workflows, and the control room client for radiation therapy treatment management.

    Machine Learning demonstrations
    The Machine Learning department at RaySearch is developing solutions for automating workflows and supporting the user in RayStation and RayCare. At ESTRO 37, RaySearch will demonstrate two RayStation applications of machine learning: automated treatment planning and automated organ segmentation. The automated planning application uses machine learning algorithms to generate a set of treatment plans in minutes, based on clinical treatment data from Princess Margaret Cancer Centre and University Medical Centre Groningen. Automated organ segmentation uses deep neural networks to generate a set of 3D organ volumes within seconds.

    RaySearch will also present the machine learning and analytics framework concept that will enable RayStation and RayCare to become learning systems.

    Lunch symposium: Advancing Cancer Treatment Through Software Innovation
    On Saturday April 21, 13:15 - 14:15, floor P1, room 11, RaySearch will hold a lunch symposium focused on how software is driving innovation in oncology.
    Moderator: Rik Westendorp, Medical Physicist, Radiotherapiegroep, Deventer, Holland

    Fight cancer with code
    Johan Löf, Founder & CEO, RaySearch Laboratories (publ), Stockholm, Sweden

    First clinical experience with RayCare 1 in a multi-institutional setting
    Carole Mercier, Radiation Oncologist, Iridium Cancer Network, Belgium

    Efficiency improvements with RayStation
    Nick West, Lead Clinical Scientist, The Northern Centre for Cancer Care, Newcastle, UK

    Questions and conclusion session
    Rik Westendorp, Medical Physicist, Radiotherapiegroep, Deventer, Holland

        
      
    About RayCare

    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    RaySearch and IBA to demonstrate first online adaptive proton workflow at ESTRO

    PDF

    RaySearch, the global leader in software for cancer treatment, and IBA, the world’s leading provider of proton therapy solutions for the treatment of cancer, will make a unique joint presentation at the ESTRO 37 Annual Meeting. The companies will demonstrate their innovative approach to optimizing the patient treatment workflow through the first online adaptive proton therapy workflow.

    The comprehensive demonstration will feature the oncology information system RayCare* and the treatment planning system RayStation from RaySearch, in combination with IBA’s adaPT Treatment Suite, composed of the adaPT Insight imaging platform and adaPT Deliver for treatment delivery.

    In an online adaptive workflow, daily cone beam images are taken and matched to the planning CT for a particular patient. Based on the daily images, an updated treatment plan can be automatically suggested to the care team at the time of a treatment session. A plan adaptation that takes the patient’s current situation into account can thus be made before treatment delivery starts. This workflow benefits patients by allowing for more accurate treatments and faster plan adaptation.

    Frederic Genin, Head of Product Management at IBA, says: “The combination of IBA’s most advanced cone beam imaging solutions and RaySearch’s treatment planning and oncology information systems will enable our future clinical partners to make online adaptive proton therapy a reality. We are very excited to see how these advanced capabilities will benefit patients around the world.”

    Björn Hårdemark, Deputy CEO of RaySearch, says: “The treatment planning technologies necessary for adaptive re-planning have long been available in RayStation, and the introduction of RayCare added the workflow components for offline adaptive treatments. Online adaptive treatment demands a tight integration of the delivery systems, and the strategic alliance between IBA and RaySearch makes this possible. This successful integration clearly shows the strength of a collaborative approach.”

    The live demonstration of the first online adaptive proton therapy workflow will take place at the IBA booth, #1400, during the ESTRO Annual Meeting in Barcelona, Spain, 20–24 April 2018.

    About IBA
    IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

    About RayCare
    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    RayStation users win treatment planning World Championships

    PDF

    In the first World Championships of Treatment Planning, arranged by ProKnow, RayStation users scored highest in two out of three planning categories. The categories were proton, VMAT and IMRT. RayStation users reached five of the ten highest scores, with all submitted plans taken into consideration. This is particularly impressive, since the next-best TPS that was used in preparing the dose planning, contributed with more than twice as many plans in comparison to RayStation.

    RayStation user Dennie Fransen, Senior Radiation Therapy Technologist at Holland Proton Therapy Centre (HollandPTC), scored highest in the proton category, with all submitted plans considered. Fransen has extensive experience in treatment planning with several different planning systems and treatment techniques. Over the last 18 months, he has been using RayStation for intensity modulated proton therapy, which is one of the most advanced and accurate radiation therapy techniques.
    "Participating in the inaugural World Championships in treatment planning was a fun experience. The ability to quickly produce high quality proton plans in RayStation was a key factor for this competition”, says Dennie Fransen.

    In the IMRT category, RaySearch research engineer Björn Andersson achieved the highest score using an automatic planning technique that he recently developed, which will be included in a future RayStation release*.
    The winning plan was thus produced with only minimal user interaction. After the competition had closed, the automatic planning technique was applied to the proton and VMAT categories as well, showing good results.
    "I am of course delighted that my technique managed to produce a winning plan. Looking forward, I am very excited about the possibilities that automatic treatment planning will bring to radiation therapy", says Björn Andersson.

    Björn Hårdemark, Deputy CEO at RaySearch, says: “I’m happy to see that RayStation users have once again achieved excellent scores in a global treatment planning competition. ProKnow has done an excellent job in creating the scenarios and scoring criteria to achieve a fair and exciting competition, and it will be interesting to monitor the impact of automatic planning techniques in future events.”

    About ProKnow World Championships:
    The objective of the World Championships of treatment planning is to determine what planner and planning system can produce the highest quality plan in an aggressive and limited timeframe. Professionals from over 30 countries participated.
    For more information about the competition, please visit: https://proknowsystems.com/

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    PDF

    RayStation selected for Proton and Carbon Ion Therapy centers in Heidelberg and Marburg, Germany

    PDF

    RayStation* has been chosen as the treatment planning system for Heidelberg Ion Beam Therapy Center (HIT) and Marburg Ion Beam Therapy Center (MIT) – The new order means that all carbon ion therapy centers in Europe have selected RayStation.

    Heidelberger Ionenstrahl-Therapiezentrum (HIT) and Marburger Ionenstrahl-Therapiezentrum (MIT) in Germany is both operational with protons and carbon ions and operates similar accelerator systems provided by Siemens AG. HIT has been in operation since 2009 and MIT has been in operation since 2015.

    RayStation was selected jointly by clinicians and researchers at HIT, MIT, Heidelberg University Hospital and the German Cancer Research Center (DKFZ), and the system will be used across the four centers. The decision was motivated by RayStation’s outstanding functionality and comprehensive support for the ion treatment technique as well as its capacity to plan for photon linacs and the TomoTherapy delivery system on the same software platform. The full RayStation installation compromises modules for proton, carbon ion and helium ion pencil beam scanning with robust biological optimization using the LEM and MKM models for radiobiological effect.

    This order is a prerequisite for also providing Helium pencil beam scanning support in RayStation to HIT. Such an agreement is under discussion with HIT and is expected to be finalized during 2018.

    Jürgen Debus, Prof. Dr.med. Dr.rer.nat. at the Heidelberg University Hospital says: “RayStation will give us ultimate flexibility to optimize the treatment plans for our patients and seamlessly integrate proton, ion and photon plans."

    Johan Löf, CEO of RaySearch, says: “A major strength of RayStation is the ability to consolidate treatment planning for diverse treatment techniques and machines. RaySearch is committed to supporting the latest clinical approaches, and we are pleased to meet the wide-ranging needs of HIT and MIT, which are truly at the forefront of cancer treatment.”

    The majority of the order will be delivered and generate income during the second quarter of 2018. 

    About HIT and MIT
    Heidelberg Ion Beam Therapy Center (HIT) and Marburg Ion Beam Therapy Center (MIT) are jointly run advanced cancer treatment facilities located in Southwest Germany. HIT at Heidelberg University Hospital was the first ion-beam therapy center in Europe to be integrated into a hospital facility and has treated more than 4,000 patients since it opened in 2009. MIT started operations in 2015, becoming Germany's second and the world's third heavy-ion therapy facility. The center’s activities are supported by University Hospital Heidelberg and the University Hospital of Giessen and Marburg.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    PDF

    Two major orders for RayStation from North America

    PDF

    RaySearch Laboratories AB (publ) has received major orders for RayStation from two radiation therapy clinics in North America. The combined order value of 6.4 MUSD (excluding service agreements), corresponding to approximately 53 MSEK, has to a large extent been delivered and is expected to generate revenue of approximately 38 MSEK in the first quarter of 2018. The remaining order value will generate revenue during the coming 15 months.

    This information is information that RaySearch Laboratories AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below on March 31, 2018 at 11.30 CET.

    For further information, please contact:

    Johan Löf, President and CEO           Tel:: +46 8 510 530 00      Email: johan.lof@raysearchlabs.com
    Peter Thysell, CFO                             Tel: +46 70 661 0559        Email: peter.thysell@raysearchlabs.com

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. In December 2017; the company launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    PDF

    Share conversion in RaySearch Laboratories AB (publ)

    PDF

    During March 2018, 200,000 Class A shares were converted to Class B shares, at the request of a shareholder. The total number of votes in RaySearch thereafter amounts to 110,377,548 votes. The total number of registered shares in RaySearch amounts to 34,282,773 shares, out of which 8,454,975 are Class A shares and 25,827,798 are Class B shares.

    According to RaySearch Laboratories AB’s (publ) Articles of Association, owners of Class A shares have the right to have such shares converted to Class B shares. A conversion reduces the number of votes in the company. When a conversion has been carried out, RaySearch is obligated by law to disclose information on changes resulting from the conversion.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    This information is information that RaySearch Laboratories AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08.30 CET on 29 March 2018.

    PDF

    United Imaging Healthcare and RaySearch join forces

    PDF

    Shanghai United Imaging Healthcare Co. Ltd. (UIH) and RaySearch Laboratories AB (publ) (RaySearch) have entered into a collaboration within which RaySearch’s treatment planning system RayStation* and radiation oncology system RayCare* will be adapted to support the UIH linear accelerators.

    Within a few short years, UIH has become a leading vendor of advanced imaging equipment, including CT, PET-CT and MRI systems. Last November, UIH introduced their first radiation therapy system, the uRT-linac506C, at CSTRO in Beijing. This hybrid CT-linac is the world’s first medical linear accelerator with fully-integrated diagnostic-quality CT imaging. It is designed from the ground-up to support adaptive radiation therapy re-planning and provides the highest precision soft-tissue-based image-guidance.

    RayStation already supports a broad range of treatment machines, radiation therapy modalities, and treatment techniques. Since day one, RayStation has focused on adaptive radiation therapy (ART), recognizing it as key to implementing personalized care and optimizing treatment outcomes. To perform ART, RayStation has a found a perfect partner in the UIH CT-linac, since the latter combines full treatment-plan-quality imaging with the latest treatment capabilities for photon therapies. The digital workflows in RayCare that are tailored for efficient adaptive radiation therapy, make ART even more accessible to all types of clinics. UIH’s CT-linac, as well as their standard linac, will be the first conventional photon linacs to be supported by RayCare.

    Johan Löf, CEO and founder of RaySearch Laboratories, says: “There has been a lack of competition in the space of conventional linacs for a long time and I very much welcome that UIH has taken the step into this market. Their CT-linac, in particular, is a great example of a sensible combination of diagnostic imaging and a therapeutic device and I look forward to adding it, as well as the standard UIH linac, to our repertoire of supported treatment systems.”

    Cheng Ni, CEO of UIH’s Radiation Therapy Business Unit, remarked: “This collaboration with RaySearch will enable us to provide a strong software suite as an option to a wide range of clinics, including the most demanding academic centers in the world. It makes it possible for clinics to use our ground-breaking CT-linac in conjunction with other delivery systems inside a single unified software platform.”
      

    About UIH
    Shanghai United Imaging Healthcare Co. Ltd. manufactures medical imaging systems and equipment. UIH was founded 2011 and the headquarter is in Shanghai’s Jiading district. Their mission is to provide medical institutions with a full range of healthcare solutions, from diagnostic imaging and radiation therapy equipment to service, training and medical IT.
      

    About uRT-linac506c
    uRT-linac506C is a fully integrated CT-linac that combines a linear accelerator with a diagnostic CT imager. Designed for the levels of patient throughput required by the world’s busiest therapy centers, the uRT-linac506C includes advanced imaging capabilities without compromising workflow efficiency or treatment performance. The system enables fraction-to-fraction personalized radiotherapy, since adjustments to the treatment plan can be made at any point during the treatment course. Using a single platform, in addition to image-guidance, clinics can perform treatment simulation without a separate CT simulator, or the need to send patients to the radiology department for imaging.
      

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
      

    About RayCare
    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.
      

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.
      

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    WPE brings PBS aperture planning with Monte Carlo dose calculation to clinical use

    PDF

    The West German Proton Therapy Centre in Essen (WPE) has clinically introduced the Monte Carlo dose calculation method for proton pencil-beam scanning. The subsidiary of University Hospital Essen, WPE is a pioneering institute and was the first proton center in Europe to use RayStation for treatment planning.

    WPE treated it first patients in 2013 and has used RayStation for all treatment planning since 2015. WPE has now become the European pioneer of Monte Carlo dose calculation in RayStation*, having recently treated the first patients planned with this method for dose calculation.

    The Monte Carlo method enables superior prediction of the dose distribution for each patient. A key feature of RayStation’s Monte Carlo dose engine is that it allows for plan optimization in pencil-beam scanning mode in conjunction with collimating patient-specific apertures. The addition of a brass aperture sharpens the lateral dose fall-off, yielding a highly conformal shaping of dose to the target volume.

    Prof. Dr. Beate Timmermann, Director of the Clinic for Particle Therapy at WPE, says: “The combination of pencil beam scanning and apertures enhances our technical options to keep the high-dose regions away from critical structures. We opt for this technique in selected brain tumor cases where organs at risk are near the target volume.”

    Johan Löf, CEO of RaySearch, says: “WPE has a history of firsts and it is gratifying to see the first patient treatment using Monte Carlo dose calculation in Europe. Monte Carlo complements the precision of proton therapy, and the dose engine in RayStation strikes the optimal balance between accurate physics modeling and speed, making it highly effective in clinical workflows. RaySearch has a strong focus on proton therapy, and we aim to keep customers at the forefront by providing the leading functionality.”


    About WPE

    The West German Proton Therapy Centre in Essen (WPE) is a leading institution for proton therapy in Germany and one of the most advanced proton therapy centers in the world. A team of specialists, including doctors, radiation therapists and medical physicists, work together to treat patients with sensitive or deeply located tumors that are either difficult or impossible to operate on. The treatment of children is also a particular specialty. WPE is a subsidiary of University Hospital Essen and thus part of the largest oncological center in Germany – the West German Cancer Centre (WTZ) – and benefits from the expertise of all oncology disciplines.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    PDF

    First clinic now live with RayCare

    PDF

    RaySearch recently announced the first clinical release of RayCare*, the next-generation oncology information system (OIS). The company is proud to announce that Iridium Cancer Network in Belgium has now started using RayCare 1 clinically to manage its treatment planning workflows, just two months after the clinical release of the system. Iridium is a pioneering clinic that has made a strong contribution to the development of RayCare, particularly with regard to features that will support coordinated activities between different institutions.

    The aim with RayCare is to create an innovative OIS that will support comprehensive cancer care. RayCare will eventually provide one workflow to connect all the oncology disciplines, enabling users to coordinate tasks fluidly and ensure optimal use of resources. Key features of RayCare 1 include task-management support for oncology workflows and an integrated planning experience in combination with RayStation 7*. Integrated communication and documentation functions are designed to ensure efficient handovers between professionals.

    Piet Dirix, MD, PhD, radiation oncologist at Iridium Cancer Network, says: “Our core mission is to contribute to an innovating radiotherapy center for integrated care. RayCare is essential to that mission, since this new OIS is designed to provide comprehensive cancer care in an extremely safe and efficient way, while fully involving patients in their treatment. The collaboration between RaySearch, Iridium and other hospitals throughout the world in developing this system has resulted in an OIS that is highly customizable. RayCare was tailored to our specific needs right from the start.”

    Eeva-Liisa Karjalainen, RayCare Project Manager, says: “RayCare will enable Iridium to use resources more efficiently and free up time for patient care. The workflows are tailored to Iridium’s processes, which makes it possible to automate time-consuming manual steps such as data import/export, task handovers and image management. This supports optimal care for each individual while reducing the burden of clinical documentation.”

    Johan Löf, CEO of RaySearch, says: “It is a dream come true to see this first clinical adoption of RayCare. The system has been designed from the ground up to meet the needs of diverse cancer centers to enable them to give the best possible treatment to their cancer patients. It is unique in supporting integrated workflows based on each patient’s need. RayCare is a truly collaborative effort made possible by the clinical expertise and high engagement of Iridium and our other clinical partners.”
         

    About Iridium Cancer Network
    The Iridium Cancer Network consists of a close collaboration in radiation oncology, and to a lesser extent medical oncology and hematology, between all 7 hospitals in the Antwerp region (GZA hospital group, ZNA hospital group, UZA, AZ KLINA, AZ Nikolaas, AZ Monica, and AZ St Jozef). There is a single radiation therapy department, which treats around 5 300 patients annually. Consequently, Iridium is by far the largest radiation therapy department in Belgium.

    About RayCare
    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    MD Anderson and RaySearch announce strategic alliance to advance radiation therapy of cancer

    PDF

    The University of Texas MD Anderson Cancer Center and RaySearch Laboratories today announced a strategic alliance with the aim of enhancing cancer radiation therapy through several initiatives, including more precisely targeting of tumors and improving upon, and making more available, an existing radiation therapy called adaptive radiation therapy (ART), currently only used at highly specialized care centers.

    Successful radiation therapy depends on the ability to delineate the precise tumor location. Since most radiation treatments are delivered over several weeks, a number of variables can compromise treatment accuracy. Traditionally, additional margins are set around the target area to allow for tumor movement and variations in how patients are positioned during treatment.

    However, these margins do not always compensate for unexpected changes in the tumor and surrounding normal tissue over the full course of radiation treatment. Adaptive radiation therapy (ART) uses frequent imaging to give an up-to-date assessment of physical changes and enable precisely tailored treatment for each patient.

    The partnership, which builds upon a previously established relationship between RaySearch and MD Anderson centered on RayCare®, RaySearch’s new oncology information system, combines MD Anderson’s clinical data and expertise with the latest technology and platforms available through RaySearch and will focus on the following areas:

    • Integration of advanced imaging into the treatment planning process to help define the tumor targets better.
    • Management of changes in the tumor that may occur during treatment, and monitoring and adjusting treatment to accommodate each patient’s individual circumstances at any point during therapy.
    • Building software components with the aim of creating a new standard of care in radiation therapy.

    “The technology to perform adaptive radiation therapy has been around for a number of years and studies have demonstrated its advantages,” said Caroline Chung, M.D., assistant professor of Radiation Oncology at MD Anderson. “However, it is a complex process that has not yet been broadly adopted in clinical practice and is largely limited to highly specialized care centers. The goal of this collaboration is to establish a methodology and workflow, clinically tested at MD Anderson, which can be streamlined and automated to enable adaptive radiation therapy on a larger scale.”

    The combination of advanced imaging data, including platforms such as RayCare and the treatment planning system RayStation, will be vital to improving the delineation of tumors. Together, this provides a novel opportunity for more personalized treatment and the development of digital workflows has the potential to improve patient care at MD Anderson and other cancer care facilities around the world.

    “This strategic partnership between MD Anderson and RaySearch is an incredibly important milestone for RaySearch,” said Johan Löf, Ph.D., CEO and founder of RaySearch. “It is one of the most ambitious collaborations that we have ever engaged in. With RayStation and RayCare as the technological platforms, paired with the expertise of MD Anderson, I believe that we can make tremendous progress toward our vision of a world where cancer is conquered.”
        
      
    About MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 45 National Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report’s “Best Hospitals” survey has ranked MD Anderson the nation’s top hospital for cancer care. MD Anderson has been ranked the leading cancer hospital for 11 of the past 14 years. The institution has been named one of the nation's top two hospitals for cancer care every year since the survey began in 1990.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton and carbon ion therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    MD Anderson Media Contact:
    Ron Gilmore
    Office: +1 713-745-1898
    Cell: +1-575-915-5790
    Email: rlgilmore1@mdanderson.org

    PDF

    Year-end Report January 1 - December 31, 2017

    PDF

    RaySearch Laboratories AB (publ)

    “In 2017, net sales rose 10 percent to SEK 585 M (531). The operating margin declined to 27 percent (38) due to lower growth for RayStation®, negative currency effects due to the weakening of the USD and higher costs due to the company’s investments in the global marketing organization and in research and development. RayStation 7 and RayCare® 1 were launched as planned and we have already secured the first order for RayCare,” says Johan Löf, President and CEO of RaySearch.

    FOURTH QUARTER (OCTOBER-DECEMBER 2017) 

    • Net sales SEK 204.9 M (191.4), of which revenues from RayStation/RayCare SEK 192.6 M (174.8)  
    • Profit after tax SEK 72.3 M (75.9) and earnings per share before/after dilution SEK 2.11 (2.21) 
    • Operating profit SEK 98.7 M (100.2) 
    • Cash flow SEK 34.6 M (56.6) 
    • Order intake excl. service agreements SEK 192.6 M (189.0), of which RayStation/RayCare SEK 183.2 M (176.3)  
    • Order backlog for RayStation/RayCare was SEK 50.0 M (67.6) at the end of the period

    TWELVE MONTHS (JANUARY-DECEMBER 2017) 

    • Net sales SEK 585.1 M (531.5), of which revenues from RayStation/RayCare SEK 531.7 M (476.0)  
    • Profit after tax SEK 117.6 M (151.4) and earnings per share SEK 3.43 (4.42) 
    • Operating profit SEK 159.7 M (200.0) 
    • Cash flow SEK 19.1 M (26.2) 
    • Order intake excl. service agreements SEK 508.4 M (501.1), of which RayStation/RayCare SEK 467.8 M (461.0)  
    • The Board of Directors proposes that no dividend be paid for 2017

    SIGNIFICANT EVENTS DURING THE FOURTH QUARTER 

    • RayStation was selected by a number of leading cancer clinics, for example, Sharp Grossmont Hospital, Anderson Regional Cancer Center and Erlanger Hospital in the US, Hôtel-Dieu de Lévis in Canada, Lausanne University Hospital (CHUV) in Switzerland, Centre Francois Baclesse in Luxemburg, Charing Cross Hospital and Hammersmith Hospital in the UK, and Maria Sklodowska-Curie Memorial Cancer Center in Poland. In addition, RayStation was also selected for a new carbon ion center at the Yamagata University Hospital in Japan and for the Apollo Proton Cancer Center in Chennai, which is the first proton therapy center in India. 
    • RayStation 7* was released with support for Mevion HYPERSCAN and integration with RayCare. RaySearch also launched µ-RayStation, a new version of the treatment planning system, which is specially adapted for pre-clinical research on small animals. 
    • RayCare 1, the next-generation oncology information system (OIS), was released as planned and the company has secured the first order for RayCare from Anderson Regional Cancer Center in the US.
          

    NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD 

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 15, 2018 at 7:45 a.m. CET.
       

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO    Tel: +46 8 510 530 00     E-mail: johan.lof@raysearchlabs.com
    Peter Thysell, CFO    Tel: +46 70 661 05 59     E-mail:
    peter.thysell@raysearchlabs.com
      

    ABOUT RAYSEARCH
    RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which was launched in December 2017 and comprises a new product area for RaySearch. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at
    www.raysearchlabs.com.

    * Regulatory approval is required in some markets.

    PDF

    Year-end Report January 1 - December 31, 2017

    PDF

    RaySearch Laboratories AB (publ)

    “In 2017, net sales rose 10 percent to SEK 585 M (531). The operating margin declined to 27 percent (38) due to lower growth for RayStation®, negative currency effects due to the weakening of the USD and higher costs due to the company’s investments in the global marketing organization and in research and development. RayStation 7 and RayCare® 1 were launched as planned and we have already secured the first order for RayCare,” says Johan Löf, President and CEO of RaySearch

    FOURTH QUARTER (OCTOBER-DECEMBER 2017) 

    • Net sales SEK 204.9 M (191.4), of which revenues from RayStation/RayCare SEK 192.6 M (174.8)  
    • Profit after tax SEK 72.3 M (75.9) and earnings per share before/after dilution SEK 2.11 (2.21) 
    • Operating profit SEK 98.7 M (100.2) 
    • Cash flow SEK 34.6 M (56.6) 
    • Order intake excl. service agreements SEK 192.6 M (189.0), of which RayStation/RayCare SEK 183.2 M (176.3)  
    • Order backlog for RayStation/RayCare was SEK 50.0 M (67.6) at the end of the period

    TWELVE MONTHS (JANUARY-DECEMBER 2017) 

    • Net sales SEK 585.1 M (531.5), of which revenues from RayStation/RayCare SEK 531.7 M (476.0)  
    • Profit after tax SEK 117.6 M (151.4) and earnings per share SEK 3.43 (4.42) 
    • Operating profit SEK 159.7 M (200.0) 
    • Cash flow SEK 19.1 M (26.2) 
    • Order intake excl. service agreements SEK 508.4 M (501.1), of which RayStation/RayCare SEK 467.8 M (461.0)  
    • The Board of Directors proposes that no dividend be paid for 2017

    SIGNIFICANT EVENTS DURING THE FOURTH QUARTER 

    • RayStation was selected by a number of leading cancer clinics, for example, Sharp Grossmont Hospital, Anderson Regional Cancer Center and Erlanger Hospital in the US, Hôtel-Dieu de Lévis in Canada, Lausanne University Hospital (CHUV) in Switzerland, Centre Francois Baclesse in Luxemburg, Charing Cross Hospital and Hammersmith Hospital in the UK, and Maria Sklodowska-Curie Memorial Cancer Center in Poland. In addition, RayStation was also selected for a new carbon ion center at the Yamagata University Hospital in Japan and for the Apollo Proton Cancer Center in Chennai, which is the first proton therapy center in India. 
    • RayStation 7* was released with support for Mevion HYPERSCAN and integration with RayCare. RaySearch also launched µ-RayStation, a new version of the treatment planning system, which is specially adapted for pre-clinical research on small animals.  
    • RayCare 1, the next-generation oncology information system (OIS), was released as planned and the company has secured the first order for RayCare from Anderson Regional Cancer Center in the US
         

    NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD 

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 15, 2018 at 7:45 a.m. CET.
       

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO    Tel: +46 8 510 530 00     E-mail: johan.lof@raysearchlabs.com
    Peter Thysell, CFO    Tel: +46 70 661 05 59     E-mail:
    peter.thysell@raysearchlabs.com
      

    ABOUT RAYSEARCH
    RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which was launched in December 2017 and comprises a new product area for RaySearch. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at www.raysearchlabs.com.
      

    * Regulatory approval is required in some markets.

    PDF

    Mitchell Cancer Institute, US, selects RayStation for TomoTherapy

    PDF

    The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Alabama, has selected RayStation* as its treatment planning system for the TomoTherapy ® System. The center also treats patients using a CyberKnife ®System and will use RayStation* for this in the future.

    MCI’s radiation therapy service is equipped with state-of-the-art Accuray´s CyberKnife and TomoTherapy System, as well as a 64-slice PET-CT scanner. The center was initially interested in RayStation’s forthcoming support for the CyberKnife System, but quickly saw that the system could meet all of its treatment planning needs into the future, including the TomoTherapy System.

    Dr. Weisi Yan, Director of the CyberKnife Program at MCI, says: “We were very impressed by the capabilities and user-friendliness of RayStation. As a leading-edge treatment center, we need the best possible technology in order to deliver outstanding care and maximize efficiency. RayStation will help us to achieve our goals.”

    Hal Hopper, Manager of MCI’s Department of Radiation Oncology, says: “RayStation is fast and effective in planning treatments for all possible techniques we are likely to offer. It is much less labor-intensive than other systems we have used. With RayStation, the physician can choose the best course of treatment more quickly.”

    Johan Löf, CEO of RaySearch, says: “MCI shares our vision of continuously advancing cancer treatment. We are very pleased to be able to meet their requirements for advanced clinical techniques as well as optimized workflows and use of resources.”
        

    About MCI
    Founded in 2000, MCI provides cancer treatment in three locations: MCI headquarters in Mobile, the MCI Kilborn Clinic in Fairhope and Monroe County Hospital in Monroeville. The center’s researchers and clinicians focus daily on the battle against cancer serving a potential catchment population of more 4.1 million people, with a singular focus of advancing cancer diagnosis, treatment and prevention in the region and beyond. Since its establishment, the center’s strategic goal has remained constant: to achieve competitiveness for future designation as an NCI Comprehensive Cancer Center and to achieve self-sustaining, long-term financial viability.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    PDF

    RayStation selected for India’s first Proton Center

    PDF

    Apollo Hospitals, Asia´s foremost integrated healthcare provider, as selected RayStation for a new proton therapy center in Chennai – the first such facility in India. The center will be equipped with IBA’s Proteus®PLUS treatment delivery system in a multi-room configuration. The setup will comprise two gantry treatment rooms and one fixed-beam treatment room, each fitted with advanced pencil beam scanning and cone beam CT technology.

    Following an extensive review of the leading systems available, RayStation was selected as the treatment planning system for the new center, which is scheduled to treat its first patients in September 2018. The choice was motivated by RayStation’s comprehensive functionality and support for all major treatment delivery systems, and RaySearch’s world-leading position in proton therapy treatment planning. An important goal for Apollo Hospitals is to unify the treatment planning workflow. The agreement includes modules for deformable registration, dose tracking, adaptive therapy and multi-criteria optimization.

    Preetha Reddy, Vice Chairperson, Apollo Hospitals Groups says: “Our resolute commitment is to make cancer conquerable and the Apollo Proton Cancer Center in Chennai underscores this etos. Over the years, we have continuously introduced the most advanced cancer care for our patients and Apollo has been honored with the trust of individuals from over 140 countries.”
    Ms. Reddy added, “Innovative technologies have been a hallmark of our cancer care protocols with RayStation reaffirms our continued investments into the best available care for modalities for our patients.”

    Johan Löf, CEO of RaySearch, says: “We are delighted to have been chosen by Apollo Hospitals for their ground-breaking introduction of proton therapy in India. Apollo shares our view of the many benefits in having a single treatment planning system for all treatment machines, and our partnership will result in high efficiency and outstanding patient care. This installation reinforces our strong and growing presence in the APAC region and our commitment to supporting the widest possible range of treatment machines.”

         

    About Apollo Hospitals
    Apollo Hospitals is widely recognized as a pioneer of private healthcare in India and established the country’s first corporate hospital in 1983. Today, it is one of Asia’s foremost integrated healthcare services providers, operating 64 hospitals as well as pharmacies, primary care and diagnostic clinics.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton and carbon ion therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    Beaumont Hospital, US, extends RayStation to Photon Therapy

    PDF

    Beaumont Hospital in Royal Oak, Michigan, has chosen to make a significant extension to its RayStation installation, which will include photon therapy in addition to proton. RayStation will be used for photon planning at Beaumont Hospital in Dearborn, where new linacs will be commissioned for the system. The purchase also includes additional functionality and licenses for proton therapy at Beaumont Hospital, Royal Oak.

    The nationally recognized cancer program at Beaumont is based on the latest treatment technologies. Beaumont initially purchased RayStation for proton therapy in 2014, and advanced features such as adaptive therapy and deformable registration are key elements of its workflow.

    “We are excited about having the opportunity to extend RayStation to our photon business,” says Craig Stevens, M.D., Ph.D., Radiation Oncologist and Chairman, Radiation Oncology at Beaumont. “It will allow us to mix proton and photon planning, ultimately streamlining and improving efficiency.”

    Xuanfeng Ding, Ph.D., Lead Proton Physicist, adds: “We often create both a photon and proton plan and compare side-by-side to determine the best treatment option for each patient. Deformable registration has been a great help in our proton center, helping us to evaluate previous dose and generate the plan sum on the current CT. In combination with the adaptive functionality, it definitely helps improves quality of patient care and workflow efficiency.

    Johan Löf, CEO of RaySearch, says: “Beaumont has an outstanding track record in using advanced technology to ensure the optimal treatment method for each patient. RayStation is an excellent fit for this approach, with comprehensive functionality to support cutting-edge techniques and the widest range of treatment machines. I look forward to a successful partnership that will benefit many patients in Michigan.”
     

    About Beaumont Hopsital
    Beaumont is Michigan’s largest healthcare system, established in 2014 to provide patients in Southeast Michigan with compassionate, extraordinary care. Beaumont Health’s culture of caring partnerships and its care delivery model of patient- and family-centered care demonstrates its commitment to engaging patients, families and the community to promote continuous healthcare improvements. With 8 hospitals, 174 health centers, close to 5,000 physicians and 38,000 employees, Beaumont Health contributes to the health and well-being of residents throughout Southeast Michigan and beyond.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton and carbon ion therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
     

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    PDF